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Abstract 
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The rise in multidrug resistant (MDR) cases of tuberculosis (TB) has led to the need for 
the development of TB drugs with different mechanisms of action. The genome 
sequence of Mycobacterium tuberculosis (Mtb) revealed twenty different genes coding 
for cytochrome P450s. CYP121A1 catalyzes a C-C crosslinking reaction of 
dicyclotyrosine (cYY) producing mycocyclosin and current research suggests that 
either mycocyclosin is essential or the overproduction of cYY is toxic to Mtb. A series 
of 1,4-dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives were designed and 
synthesised as cYY mimics. The derivatives substituted in the 4-position of the phenyl 
rings with halides or alkyl group showed promising antimycobacterial activity (MIC 
6.25 g/mL), with the more lipophilic branched alkyl derivatives displaying optimal 
binding affinity with CYP121A1 (iPr KD = 1.6 M; tBu KD = 1.2 M). Computational 
studies revealed two possible binding modes within the CYP121A1 active site both of 
which would effectively block cYY from binding.  
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1. Introduction 
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Tuberculosis (TB) is the ninth leading cause of death worldwide, ranking above Human 
Immunodeficiency Virus (HIV/AIDS). In 2017, the estimated TB deaths were 1.3 
million among HIV-negative people and 300,000 among HIV-positive people, and the 
estimated incident TB cases were 10.0 million worldwide.1 The standard therapeutic 
regimens involve the combination of four first-line drugs, often isoniazid, rifampicin, 
pyrazinamide and either streptomycin or ethambutol, depending upon whether there is 
a latent or active type of infection.2 Although the current medications for treating drug-
sensitive TB are effective when there is optimum adherence of patients, a common 
problem in real-life conditions appears with TB-infected patients who generally do not 
adhere strictly to dosages.3,4  
The duration for treating drug-sensitive TB is usually 6 months with the four most 
effective agents from the first-line oral drugs administered in a single prescription for 
the first two months of treatment, and two of the four taken for a subsequent four 
months in the continuation phase, resulting in patient adherence issues.5 When 
administered in sub-optimum conditions, chronic cases of infectious drug-resistant TB 
appear. Long treatment durations are usually required because Mycobacterium 
tuberculosis (Mtb), the causative pathogen, can develop a dormancy phenotype under 
nutrient depletion and anaerobiosis conditions which is tolerant to several anti-TB 
drugs.6,7 The development of novel anti-TB drugs has become a priority in view of the 
increasing global incidence of strains resistant to at least rifampicin and isoniazid 
(MDR-TB), or to rifampicin, isoniazid and one of the injectable second-line anti-TB 
drugs as well as to any of the fluoroquinolone drug series (XDR-TB),1 in addition to 
the interactions between anti-TB drugs and antiretroviral medications, and the need to 
treat latent TB-infected patients before the bacteria transform into their active form.8 
Studies following the unraveling of the genome sequence of the virulent Mtb H37Rv 
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strain revealed numerous genes with unknown functions.9 Among these were twenty 
different cytochrome P450 (CYP) genes coding for P450s.10 This large number of CYP 
genes was uncommon for a bacterium and, as a result, studies over the past twenty years 
have focused on characterizing these Mtb P450s, several of which play crucial roles in 
the survival of Mtb. Subsequent genome studies with M. smegmatis revealed several 
P450s, confirming the multiple important functions for the P450s in the 
actinobacteria.11 
 
 
Figure 1. Cyclodityrosine synthase and CYP121A1 reactions to produce the cyclic dipeptide, 
cyclo-L-Tyr-L-Tyr (cYY), and the novel secondary metabolite mycocyclosin. 
 
CYP121A1 (mycocyclosin synthase) was shown to be essential for bacterial growth by 
in vitro gene knockout studies.12-14 Also, CYP121A1, along with CYP128A1 and 
CYP141A1, are the only Mtb P450s that appear to be conserved within members of the 
Mtb complex because their homologues do not appear in the genomes of the other 
members of the actinobacteria family. The first evidence of CYP121A1 function in Mtb 
was derived from its gene position, which is located in an operon harboring two 
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enzymes involved in the formation of cyclo-di-L-tyrosine (cYY). The first enzyme is a 
cyclodipeptide synthase (encoded by Rv2275), which uses aminoacyl-tRNA 
synthetases (L-tyrosyl-tRNATyr) to catalyse the ATP-independent formation of cYY 
(Figure 1).15,16 Then, CYP121A1 (encoded by Rv2276) catalyzes a C-C crosslinking 
reaction between the respective carbons in the ortho position of the phenolic hydroxyl 
of cYY, producing mycocyclosin (Figure 1). Rv2276 was found to be an essential Mtb 
gene, and it was suggested that either mycocyclosin was essential or the overproduction 
of cYY is toxic.14,17 Assays conducted on CYP121A1 utilising a ferredoxin and 
ferredoxin reductase system demonstrated that CYP121A1 catalyzes multiple turnovers 
of cYY in a complicated multistep process to form mycocyclosin as the single major 
product in the presence of NADPH.17 
 
A B 
 
 
Figure 2. (A) Flexible alignment of cYY (yellow) and lead compound (cyan) showing 
overlap (B) Binding affinity and MIC data for lead compound. 
 
In the development of CYP121A1 inhibitors, we have described several series of 
compounds with chemical scaffolds that mimic the natural substrate cYY.18,19 From 
these series 1,4-dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives were identified 
as potential leads for further development.18 Flexible alignment of these derivatives 
with cYY showed good overlap (Figure 2) suggesting they would occupy a similar area 
as cYY within the CYP121A1 active site, while the addition of an azole haem-binding 
 6 
group (imidazole) may allow direct interaction between the compound and the haem 
iron.  
The lead compound showed weak binding affinity, as determined by UV-vis optical 
titration, and modest inhibitory activity against Mtb (Figure 2). Therefore, the aim of 
this study was to develop this series of compounds, through varying the substituent on 
the benzene rings, and to explore the structure-activity relationship to improve both 
binding affinity with CYP121A1 and MIC against Mtb.
 
 
Scheme 1. Reagents and conditions: (i) EtOH, r.t., o/n (ii) NaBH4, MeOH, r.t., 4 h (iii) Et3N, 
2,3-dibromopropionic acid ethyl ester, toluene, 80 °C, o/n (iv) LiAlH4, THF, r.t., o/n (v) SOCl2, 
CH2Cl2, r.t., 48 h (vi) (a) Imidazole, K2CO3, CH3CN, 45 °C, 1 h (b) chloride 7, 70 °C, 48 h. 
 
2. Results and Discussion 
2.1 Chemistry 
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The imidazole products (8) were obtained from a six-step synthetic route (Scheme 1). 
Substituted benzaldehyde derivatives (1) were reacted with ethylenediamine (2) in 
ethanol for 6 h at room temperature to give the di-Schiff base (di-imine) (3), which  
precipitated from the reaction as pure crystalline solids in high yields of 81-99%. The 
imine bond was reduced by NaBH4 followed by careful aqueous work-up while cooling 
in an ice bath to give the diamines (4) in good yields (75-97%) with the exception of 
the pyridinyl derivatives (4i and 4j), which were obtained in yields of 29 and 31% 
respectively owing to their water solubility. The synthesised diamines (4) on reaction 
with ethyl 2,3-dibromopropionate20 resulted in the formation of ethyl 1,4-
bis(substituted) piperazine-2-carboxylate (5) with yields in the range of 65-85%. 
Piperazine, as a six-membered cyclic system, can exist in both chair and boat 
conformations. The lowest energy and most stable conformation for the synthesised 
esters, using the conformational import algorithm21 in MOE22 followed by optimisation 
using the PM3 model Hamiltonian23 is shown in Figure 3. 
From the proposed 3D structure, the axial conformation for the ester moiety at C-
2 was preferred,24 this conformation of the ester intermediates was analysed by 1H 
NMR and 2D COSY experiments. The H-2 proton had vicinal three-bond couplings 
across single bonds with both axial and equatorial H-3 protons, and appeared as doublet 
of doublets (dd) in the 1H NMR spectra in derivatives 5a, 5c, 5e, 5h and 5i with 
coupling constants in the range of 3.4-3.6 Hz for the vicinal equatorial-equatorial 
couplings, and larger values in the range of 5.5-6.0 Hz for the vicinal equatorial-axial 
couplings. In some derivatives, the H-2 proton couplings appeared as a multiplet (m) 
as seen in 5b and 5d, or interfered with other protons as seen in 5f, 5g and 5j. Geminal 
spin-spin couplings were conserved between the H-7 protons and the H-8 protons, and 
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in the 1H NMR spectra, each proton appeared as a doublet (d) with a geminal coupling 
constant in the range of 13.0-14.0 Hz.  
 
Figure 3. Ethyl 1,4-bis(4-fluorobenzyl)piperazine-2-carboxylate (5a) chair conformation with 
vicinal and geminal couplings of H-2, H-7 and H-8 protons.  
 
The synthesised esters (5) were reduced to the corresponding primary alcohols (6) 
by LiAlH4 after overnight stirring at room temperature with yields in the range of 56-
91% obtained. Conversion of the alcohols (6) to the alkyl chlorides proceeded through 
a nucleophilic substitution SN2 mechanism using thionyl chloride (10 equivalents) at 
room temperature for 48 h. A trial to accelerate the chlorination reaction rate was done 
by refluxing the synthesised alcohol with thionyl chloride (2 equivalents) at 80 °C, but 
complex mixtures were obtained, and the products could not be separated or identified 
upon refluxing, especially for the halide derivatives (7a-7d). The yields of the chloride 
products (7) from reaction at room temperature for 48 h were in the range of 50-88%. 
The imidazolate ion, which acts as a nucleophile, was formed in situ by reacting 
imidazole with a base, for 1 h at 45 °C in acetonitrile, followed by a SN2 reaction 
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between the imidazolate and the synthesised alkyl chloride (7). When sodium hydride 
(60% dispersion in mineral oil) was used as a base according to the reported method,18 
a complex mixture was obtained, and the product could only be separated in a very low 
yield (< 10%). Potassium carbonate was selected as the optimum base, and the reaction 
was complete after refluxing at 70 °C for 48 h with yields in the range of 51-69%. 
 
 
 
 
Figure 4. 2-((1H-Imidazol-1-yl)methyl)-
1,4-bis(4-(tert-butyl)benzyl)piperazine 
(8h) chair conformation after energy 
minimisations to explain vicinal and 
geminal couplings between H-9, H-2, H-
7, H-8 protons.  
 
A characteristic feature for the final imidazoles was the geminal and vicinal proton-
proton coupling,. The doublet of doublets (dd) at 4.28-4.29 ppm was assigned to the 
geminal (J = 13.8-14.0 Hz) and vicinal (J = 4.3-4.4 Hz) couplings of the H-9a proton 
with H-9b and H-2 protons, respectively. The doublet of doublets at 4.20-4.21 ppm was 
assigned to the geminal (J = 13.8-14.0 Hz) and vicinal (J = 7.6-8.0 Hz) coupling of the 
H-9b proton with H-9a and H-2 protons, respectively. The vicinal spin-spin coupling 
constants illustrated the difference in the chemical shifts between H-9a and H-9b 
protons. Vicinal spin-spin coupling constants were generally in the range of 6-8 Hz and, 
as the proton was closer to the imidazole group (electron-deficient group), smaller 
vicinal J values were noticed. From the proposed 3D-structure after energy 
minimisations (Figure 4), the H-9a proton appeared to be closer to the imidazole group 
than the H-9b proton. Consequently, the H-9a proton was less shielded and its vicinal 
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coupling constant was less than 6.0 Hz while the H-9b proton was more shielded and 
its vicinal coupling constant was within the range of 6-8 Hz.  
 
2.2 CYP121A1 Ligand Binding Affinity 
The CYP121A1 binding affinity (KD) of the various compounds was determined by 
UV-vis optical titration.25 Binding titrations were carried out for the synthesised 
imidazoles (8), which showed a type II (inhibitor-like) red shift in the haem Soret peak 
to a longer wavelength (Figure 5, for example 8h) indicating that, in the solution state, 
most of these compounds coordinate either (i) directly to the CYP121A1 haem iron or 
(ii) indirectly to the haem iron through an interstitial water molecule.  
 
Figure 5. UV-Vis optical binding titration for compound 8h binding to CYP121A1. The 
left hand panel shows data from a compound 8h titration with CYP121A1 (~4.7 M) with the 
ligand-free spectrum as a thick black line, spectra following progressive additions of 8h as thin 
solid lines, and the final near-saturated protein spectrum shown as a thick red line. The inset 
shows overlaid difference spectra generated by the subtraction of the starting spectrum from 
each consecutive ligand-bound spectrum collected in the titration. The right hand panel shows 
a plot of compound 8h-induced absorbance change – calculated as the difference between the 
peak and trough in the difference spectra in the left hand panel, using the same wavelength pair 
(429 and 392 nm, respectively) throughout. Data were fitted using the Hill equation to give a 
8h KD value of 1.2 ± 0.1 M.  
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Halogenated derivatives (8b-8d) displayed moderate binding affinity with the 
best KD value observed for the 3,5-diCl compound 8d. The 4-F compound 8a was noted 
to undergo photo- and thermal-decomposition in this assay so the data obtained was not 
reliable.  
 
Table 1. Binding affinity (KD) values for compounds against M. tuberculosis H37Rv 
 
Compound R KD (M)a Soret peak shift (nm) 
Lead H 1968 ± 137 416.5 to 417.5 
8b 4-Cl 26.8 ± 7.9 416.5 to 419 
8c 4-Br 11.9 ± 2.1 416.5 to 421 
8d 3,5-diCl 8.1 ± 0.4 416.5 to 419 
8e 4-OCH3 42.0 ± 14.3 416.5 to 419.5 
8f 4-CH2CH3 3.7 ± 0.1 416.5 to 423.5 
8g 4-CH(CH3)2 1.6 ± 0.1 416.5 to 422.5 
8h 4-C(CH3)3 1.2 ± 0.1 416.5 to 419.5 
8i Pyridin-4-yl 39.2 ± 7.9 416.5 to 419.5 
8j Pyridin-3-yl 489 ± 27 416.5 to 421.5 
Fluconazole  8.6 ± 0.2  
Clotrimazole  0.07 ± 0.01  
cYY  5.8 ± 0.2  
acompound 8a (R = 4-F) noted to undergo photo- and thermal-decomposition during this assay. 
 
The lipophilic derivatives had the best binding of the imidazole nitrogen to the 
haem iron with KD values of 3.7 ± 0.1, 1.6 ± 0.1 and 1.2 ± 0.1 M for 8f, 8g and 8h, 
respectively, while the natural substrate cYY had a KD value of 5.8 ± 0.2 M. The 
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moderately hydrophilic 4-OMe (8e) and pyridines (8i and 8j) had weak binding affinity 
to CYP121A1 (Table 1). Compounds 8f and 8g induce the most extensive Soret 
absorbance shifts (416.5 to 422.5/423.5 nm), suggesting that the CYP121A1 haem iron 
is predominantly coordinated by a direct imidazole nitrogen bond in these cases. 
Compounds 8b-8e and 8h-8j show less extensive Soret red shifts on binding the 
CYP121A1 haem, suggesting that ligation modes in these cases may involve imidazole 
nitrogen interactions with haem iron mediated through an interstitial water ligand.  
 
2.3 MIC determination against Mycobacterium tuberculosis 
 The derivatives were screened against M. tuberculosis H37Rv by the REMA 
(Resazurin Microtiter Assay) method.26 With the exception of the pyridyl compounds 
8i and 8j, which were inactive (MIC >100 g/mL), all the compounds were more active 
than the lead parent compound (MIC 50 g/mL). In the halogenated series, the 4-
monosubstituted benzene ring derivatives 8a-8c showed good inhibitory activity (MIC 
6.25 g/mL) compared with the 3,5-dichloro substituted derivative 8d (MIC 25 g/mL). 
The alkyl substituted series all showed promising inhibitory activity (MIC 6.25 g/mL), 
while the more hydrophilic 4-methoxy derivative (8e) was less effective (MIC 25 
g/mL). 
 
 
 
 
Table 2. MIC values for compounds against M. tuberculosis H37Rv  
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Compound R Mol.Wt. MIC 
(g/mL) cLogPa 
Lead H 346.469 50 3.56 
8a 4-F 382.450 6.25 3.87 
8b 4-Cl 415.359 6.25 4.67 
8c 4-Br 504.261 6.25 5.21 
8d 3,5-diCl 484.249 25 5.79 
8e 4-OCH3 406.521 25 3.3 
8f 4-CH2CH3 402.575 6.25 5.36 
8g 4-CH(CH3)2 430.628 6.25 6.02 
8h 4-C(CH3)3 458.681 6.25 6.97 
8i Pyridin-4-yl 348.445 >100 0.88 
8j Pyridin-3-yl 348.445 >100 0.88 
Fluconazole  306.271 >100 0.87 
Clotrimazole  344.837 20 5.97 
cYY  326.347 - 1.26 
a
 cLogP was determined using Crippen’s fragmentation 
 
 
 
 
 
 
 
2.4 Molecular Modelling   
Molecular modelling of the compounds was performed using Molecular Operating 
Environment (MOE) sofware and the crystal structure of cYY co-crystallised with 
CYP121A1 (PDB 3G5H).17 Most of the compounds displayed two binding modes 
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when docked within the CYP121A1 active type, both of which show indirect binding 
with the haem via an interstitial water molecule. 
A      B 
   
Figure 6. Docking of representative piperazines (cyan) (A) 8b in binding mode 1 and (B) 8g 
in binding mode 2 in the CYP121A1 active site compared with cYY (magenta). [Haem 
(orange), water molecules (red spheres)] 
 
The first docking mode (mode 1) mimicked the cYY conformation as illustrated by the 
chloro derivative 8b (Figure 6A). The most consistent binding interactions were 
observed between the imidazole ring and Arg386 via a water molecule and the 
protonated piperazine NH+ and Met86 effectively bridging the active site above the 
haem (Table 2). In the second binding mode (mode 2) a more open/flexible 
conformation was observed as illustrated by the isopropyl derivative 8g (Figure 6B). 
This increased flexibility is possible owing to the piperazine ring which can exist in 
both chair and boat conformations. In mode 2, binding interactions were observed 
between the imidazole and a number of different amino acids (e.g. Asn74, Gly283, 
Gln385 and Arg386) via a water molecule with additional binding between the 
protonated piperazine NH+ and Met86. The pyridine derivatives 8i and 8j formed 
additional H-bonding interactions through the two pyridine rings. Multiple 
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hydrophobic interactions were observed between the piperazines (8) for both binding 
modes 1 and 2 including residues Met62, Thr77, Val78, Val82, Val83, Asn85, Leu164, 
Ala167, Phe168, Thr229, Ala233, Gly232, Phe280 and Leu284. For the unsubstituted 
lead compound and the fluoro (8a), chloro (8b) and pyridine (8i and 8j) derivatives, 
binding mode 1 was energetically prefered (Table 2).  
 
Table 2. Computational binding energies of piperazines 8 and CYP121A1 
Compound R Mode 1 
S-value (kcal/mol) 
Mode 2 
S-value (kcal/mol) 
 
Lead H -4.69 -2.97 
8a 4-F -6.29 -4.61 
8b 4-Cl -4.53 -4.23 
8c 4-Br - -2.78 
8d 3,5-diCl - -3.64 
8e 4-OCH3 -4.73 -4.79 
8f 4-CH2CH3 -3.34 -4.29 
8g 4-CH(CH3)2 -3.18 -4.21 
8h 4-C(CH3)3 - 0.04 
8i Pyridin-4-yl -5.00 -2.35 
8j Pyridin-3-yl -5.32/-6.58 -4.26 
S-value = lowest binding energy 
 
The methoxy derivative (8e) showed comparable S-values for binding modes 1 and 2, 
while the ethyl (8f) and isopropyl (8g) derivatives had improved S-values for binding 
mode 2 (Table 2). For the more bulky bromo (8c), dichloro (8d) and tert-butyl (8h) 
derivatives only binding mode 2 was observed with the tert-butyl derivative the least 
energetically favourable. Two possible mode 1 orientations were observed for the 3-
pyridyl derivative (8j) with indirect interaction with the haem via a water molecule 
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either through imidiazole (S-value -5.32) or through one of the pyridine rings (S-value 
-6.58.).  
To investigate the binding modes further molecular dynamics simulations were run for 
50ns for the CYP121A1 and isopropyl derivative (8g) and tert-butyl derivative (8h) 
complexes using the Desmond programme of Maestro.27,28 For the isopropyl (8g)-
CYP121A1 complex, the RMSD changed from 1.2 Å at zero time to 2.1 Å at ~ 10 ns; 
then the protein was equilibrated with no evident RMSD fluctuations observed and the 
ligand aligned.  For the tert-butyl (8h)-CYP121A1 complex, equilibrium and ligand 
alignment required a longer run time with the RMSD changing from 0.8 Å at zero time 
to 2.0 Å at ~ 30 ns. (Figure 7A). Protein interactions with the ligand were checked 
throughout the simulation and interactions ordered by their type; specifically hydrogen 
bonds, hydrophobic, ionic, and water bridges (Figure 7B). The isopropyl derivative (8g) 
formed more interactions over the course of the 50ns simulation compared with the 
tert-butyl derivative (8h). As illustrated in Figure 7C, water bridge interactions between 
the imidazole and Asp282 and Gln385, and the protonated piperazine and Val83 were 
significant for 8g with additional hydrophobic interactions between the 4-iPr-phenyl 
rings and Phe168 and Pro285. For 8h the major contributor was a water bridge 
interaction between the imidazole ring and Arg386, with additional binding interactions 
between one of the tBu-phenyl rings and His343 (- stacking) and Phe168 
(hydrophobic) (Figure 7C). 
 
 
iPr (8g) tBu (8h) 
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A 
B 
 
C 
 
 
 
Figure 7. (A) Protein (blue) and ligand (red) root mean square of the CYP121A1-8g and 8h complexes 
(B) Illustration of protein interactions with the ligand. The red column means ionic bond, green column 
a hydrogen bond, blue column water bridges, and a purple column a hydrophobic bond. The stacked bar 
charts are normalised over the course of the trajectory: for example, a value of 0.5 suggests that for 50% 
of the simulation time, the specific interaction is maintained (C) A schematic of detailed ligand atom 
interactions with the protein residues. Interactions that occur more than 30.0% of the simulation time in 
the selected trajectory (0.00 through 50.05 nsec), are shown (note: it is possible to have interactions with 
>100% as some residues may have multiple interactions of a single type with the same ligand atom e.g. 
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the ARG side chain has four H-bond donors that can all hydrogen-bond to a single H-bond acceptor). 
 
Sterically, the transition from an isopropyl (8g) to a tert-butyl (8h) would appear 
sufficient to hinder closer binding interaction. As shown in Figure 8, the isopropyl 
derivative (8g) is able to take a position within the active site that is comparable (mode 
1 binding) with the natural substrate cYY although one of the iPr-phenyl rings deviates 
from the cYY position through hydrophobic interaction with Pro285. However the tert-
butyl derivative (8h) stabilises in the more open/flexible mode 2 conformation, with 
one of the tBu-phenyl rings deviating substantially, most likely owing to the reduction 
in conformational space within the binding pocket composed of Met62, Val82, Val83, 
Asn85 and Met86 (Figure 6). 
 
Figure 8. Positioning of the isopropyl derivative (8g, cyan) and tert-butyl derivative (8h, 
magenta) compared with cYY (yellow) after molecular dynamics simulation. 
 
Both indirect binding modes 1 and 2 are possible and both would be effective in 
blocking the natural substrate cYY from binding at the active site. Crystallographic 
studies are needed to explore binding modes further. 
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3. Conclusions 
With the exception of the pyridyl derivatives (8i and 8j), all the new piperazine 
derivatives showed improved binding affinity to CYP121A1 and inhibitory activity 
against Mtb compared with the lead compound. Preliminary SAR for the described 1,4-
dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives would suggest that 4-
substitution of the benzyl rings with either halides (8a-8c) or alkyl substitutents (8f-8h) 
is beneficial for antimycobacterial activity with improved activity (MIC = 6.25 g/mL) 
compared with clotrimazole (MIC = 20 g/mL) (Table 1). Only one compound did not 
have substitution in the 4-position, namely the 3,5-dichloro derivative (8d), which had 
a reduced inhibitory activity compared with clotrimazole, however mono-substitutions 
in the 2- and 3-positions have not been investigated thus far and will be the focus of 
further studies to determine effect on binding and inhibitory activity.  Two binding 
modes were observed from molecular modeling studies with the larger substituents (Br, 
3,5-diCl, alkyl) showing a preference for the more open binding mode 2, while smaller 
substituents (F, Cl) showed a preference for the more compact binding mode 1 and 
more closely resemble the conformation of cYY (Table 2, Figure 6). The alkyl 
derivatives (8f-8h) were optimal with respect to binding affinity (KD = 3.7, 1.6 and 1.2 
M, respectively), with the ethyl (8f) and isopropyl derivatives (8g) inducing the most 
extensive Soret absorbance shifts (416.5 to 422.5/423.5 nm) (Table 1). However, 
binding affinity did not clearly correlate with MIC, for example, the 4-chloro derivative 
(8b) and the tert-butyl derivative (8g) showed similar MIC values (6.25 g/mL) but 
had completely different binding affinity to CYP121A1 (26.8 ± 7.9 compared with 1.6 
± 0.1M), suggesting different ligation modes with either indirect or direct haem 
coordination.  
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These piperazine derivatives are useful compounds for further development with future 
studies focusing on replacement of one of the phenyl rings to optimise positioning 
within the binding pocket composed of Met62, Val82, Val83, Asn85 and Met86 
identified from the computational studies as restricting optimal fit within the 
CYP121A1 active site. 
 
4. Experimental Section 
4.1 General Experimental 
All chemicals, reagents and solvents were purchased from Sigma-Aldrich, Fisher 
Scientific, Alfa-Aesar, Fluka and Acros Chemicals. Whenever required, solvents were 
dried prior to use as described by the handbook Purification of Laboratory Chemicals 
and stored over 4 Å molecular sieves under nitrogen. Flash column chromatography 
was performed with silica gel (230-400 mesh) (Merck) and TLC was performed on pre-
coated silica gel plates (Merck Kiesel gel 60F254, BDH). Melting points were 
determined on an electrothermal instrument (Gallenkamp), and are uncorrected. 
Compounds were visualised by irradiation with UV light at 254 nm and 365 nm or by 
using KMnO4 stain or vanillin stain followed by heating. NMR spectra were recorded 
on a Bruker AVANCE DPX500 spectrometer operating at 500,125 and 470 MHz for 
1H, 13C and 19F NMR, respectively, and auto calibrated to the deuterated solvent 
reference peak. The assignments were made using one-dimensional (1D) and two-
dimensional (2D) HSQC and COSY spectra. Chemical shifts are given in δ relative to 
tetramethylsilane (TMS); the coupling constants (J) are given in Hertz. TMS was used 
as an internal standard (δ = 0 ppm) for 1H NMR and CDCl3 served as an internal 
standard (δ = 77.0 ppm) for 13C NMR. Multiplicity is denoted as s (singlet), br s (broad 
singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet) or 
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combinations thereof. High resolution mass spectra (HRMS) were determined at the 
EPSRC National Mass Spectrometry Facility at Swansea University and Medac Ltd., 
Brunel Science Centre, Surrey using ESI (Electrospray Ionisation). The following 
compounds were prepared as previously described: diimines 3a-3c, 3e and 3g-3j;29-34 
diamines 4a-4c, 4e-4f and 4i;29,30,34,35  ethyl 1,4-bis(4-methoxybenzyl)piperazine-2-
carboxylate (5e), (1,4-bis(4-methoxybenzyl)piperazin-2-yl)methanol (6e) and 2-
(chloromethyl)-1,4-bis(4-methoxybenzyl)piperazine (7e).18 All compounds were more 
than 95% pure. 
4.2 Chemistry 
4.2.1. General method for the preparation of diimines (3). To a stirred solution of 
benzaldehyde (1) (2 m.eq.) in ethanol (1mL/mmol of benzaldehyde), was added 
ethylenediamine (2) (1 m.eq.) dropwise. The reaction mixture was stirred for 6 h at 
room temperature, and the precipitated white coloured crystals were collected by 
filtration, washed with diethyl ether and dried to give the desired diimine. 
4.2.1.1. N,N´-(Ethane-1,2-diyl)bis(1-(3,5-dichlorophenyl)methanimine) (3d). Prepared 
from 3,5-dichlorobenzaldehyde (1d) (5 g, 28.6 mmol). Product obtained as a white solid, 
yield 5.10 g (96%). M.p. 130-132 oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.84. 1H 
NMR (CDCl3): δ 8.34 (s, 2H, 2 x CH=N), 7.74 (d, J = 1.9 Hz, 4H, Ar), 7.71 (t, J = 1.9 
Hz, 2H, para-Ar), 3.91 (s, 4H, 2 x CH2). 13C NMR (CDCl3): δ 161.3 (2 x CH=N), 135.7 
(2 x C, Ar), 135.3 (4 x C, Ar), 129.9 (2 x CH, para-Ar), 129.3 (4 x CH, Ar), 61.2 (2 x 
CH2). [ESI-HRMS] calculated for C16H13Cl4N2: 372.9833 [M+H]+. Found: 372.9840 
[M+H]+. 
4.2.1.2. N,N´-(Ethane-1,2-diyl)bis(1-(4-ethylphenyl)methanimine) (3f). Prepared from 
4-ethylbenzaldehyde (1f) (10 mL, 72.96 mmol). Product obtained as a white solid, yield 
9.89 g (93%). M.p. 68-70 oC. TLC (4:1 petroleum ether/EtOAc), Rf = 0.84. 1H NMR 
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(CDCl3): δ 8.29 (s, 2H, 2 x CH=N), 7.62 (d, J = 8.1 Hz, 4H, Ar), 7.26 (d, J = 8.0 Hz, 
4H, Ar), 3.84 (s, 4H, 2 x CH2), 2.62 (q, J = 7.6 Hz, 4H, 2 x CH2CH3), 1.17 (t, J = 7.6 
Hz, 6H, 2 x CH2CH3). 13C NMR (DMSO-d6): δ 162.2 (2 x CH=N), 147.1 (2 x C, Ar), 
134.2 (2 x C, Ar), 128.5 (4 x CH, Ar), 128.0 (4 x CH, Ar), 61.5 (2 x CH2), 28.5 (2 x 
CH2), 15.8 (2 x CH3). [ESI-HRMS] calculated for C20H25N2: 293.2018 [M+H]+. Found: 
293.2033 [M+H]+. 
4.2.2. General method for the preparation of diamines (4). To an ice-cooled stirred 
suspension of diimine (3) (1 m.eq.) in methanol (10 mL/mmol) was added sodium 
borohydride (4.6 m.eq.) in portions. The reaction mixture was stirred for 4 h at room 
temperature. After the reaction was complete, methanol was evaporated under vacuum 
and cold water (10 mL/mmol) was added to the remaining residue until cessation of 
effervescence. The mixture was extracted with EtOAc (10 mL/mmol), and the organic 
layer was washed with water (2 x 10 mL/mmol), brine (2 x 10 mL/mmol), dried 
(MgSO4) and evaporated under vacuum. 
4.2.2.1. N1,N2-Bis(3,5-dichlorobenzyl)ethane-1,2-diamine (4d). Prepared from N,N'-
(ethane-1,2-diyl)bis(1-(3,5-dichlorophenyl)methanimine) (3d) (5.0 g, 13.36 mmol). 
Product obtained as a white solid, yield 4.41 g (87%). M.p. 106-108 oC. TLC (2:1 
petroleum ether/EtOAc), Rf = 0.12. 1H NMR (CDCl3): δ 7.28 (m, 2H, para-Ar), 7.26 
(m, 4H, Ar), 3.77 (s, 4H, 2 x CH2), 2.76 (s, 4H, 2 x CH2), 1.79 (br s, 2H, 2 x NH). 13C 
NMR (CDCl3): δ 143.6 (2 x C, Ar), 135.0 (4 x C, Ar), 127.2 (2 x CH, Ar), 126.5 (4 x 
CH, Ar), 52.8 (2 x CH2), 48.4 (2 x CH2). [ESI-HRMS] calculated for C16H17Cl4N2: 
377.0146 [M+H]+. Found: 377.0159 [M+H]+. 
4.2.2.2. N1,N2-Bis(4-isopropylbenzyl)ethane-1,2-diamine (4g). Prepared from N,N'-
(ethane-1,2-diyl)bis(1-(4-isopropylphenyl)methanimine) (3g) (10.4 g, 32.76 mmol). 
Product obtained as a white solid, yield 9.89 g (93%). M.p. 58-60 oC. TLC (2:1 
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petroleum ether/EtOAc), Rf = 0.51. 1H NMR (CDCl3): δ 7.22 (d, J = 8.2 Hz, 4H, Ar), 
7.16 (d, J = 7.8 Hz, 4H, Ar), 3.62 (s, 4H, 2 x CH2), 2.85 (m, 2H, 2 x CH(CH3)2), 2.57 
(s, 4H, 2 x CH2), 1.49 (br s, 2H, 2 x NH), 1.18 (d, J = 6.8 Hz, 12H, 4 x CH3). 13C NMR 
(DMSO-d6): δ 146.9 (2 x C, Ar), 138.9 (2 x C, Ar), 128.3 (4 x CH, Ar), 126.4 (4 x CH, 
Ar), 53.3 (2 x CH2), 48.9 (2 x CH2), 33.6 (2 x CH(CH3)2), 24.43 (4 x CH3). [ESI-
HRMS] calculated for C22H33N2: 325.2638 [M+H]+. Found: 325.2643 [M+H]+. 
4.2.2.3. N1,N2-Bis(4-(tert-butyl)benzyl)ethane-1,2-diamine (4h). Prepared from N,N'-
(ethane-1,2-diyl)bis(1-(4-tert-butylylphenyl)methanimine) (3h) (7.0 g, 20.08 mmol). 
Product obtained as a colourless oil, yield 6.5 g (92%). TLC (2:1 petroleum 
ether/EtOAc), Rf = 0.53. 1H NMR (DMSO-d6): δ 7.31 (d, J = 10.0 Hz, 4H, Ar), 7.21 
(d, J = 10.0 Hz, 4H, Ar), 3.61 (s, 4H, 2 x CH2), 2.56 (s, 4H, 2 x CH2), 1.99 (br s, 2H, 2 
x NH), 1.26 (s, 18H, 6 x CH3). 13C NMR (DMSO-d6): δ 149.2 (2 x C, Ar), 138.3 (2 x 
C, Ar), 128.1 (4 x CH, Ar), 125.2 (4 x CH, Ar), 53.1 (2 x CH2), 48.7 (2 x CH2), 34.6 (2 
x C), 31.7 (6 x CH3). [ESI-HRMS] calculated for C22H37N2: 353.2951 [M+H]+. Found: 
353.2948 [M+H]+. 
4.2.2.4. N1,N2-Bis(pyridin-3-yl methyl)ethane-1,2-diamine (4j). Prepared from N,N'-
(ethane-1,2-diyl)bis(1-(pyridine-3-yl)methanimine) (3j) (11.57 g, 48.57 mmol). 
Product obtained as a yellow oil, yield 3.7 g (31%). TLC (2:1 petroleum ether/EtOAc), 
Rf = 0.12. 1H NMR (DMSO-d6): δ 8.84 (s, 2H, pyridine), 8.60 (m, 2H, pyridine), 8.15 
(t, J = 5.8 Hz, 2H, pyridine), 7.41 (d, J = 5.7 Hz, 2H, pyridine), 3.85 (s, 4H, 2 x CH2), 
3.71 (s, 4H, 2 x CH2), 2.46 (br s, 2H, 2 x NH). 13C NMR (DMSO-d6): δ 150.3 (2 x CH, 
pyridine), 148.8 (CH, pyridine), 148.7 (CH, pyridine), 136.7 (2 x CH, pyridine), 134.7 
(C, pyridine), 133.9 (C, pyridine), 123.7 (2 x CH, pyridine), 53.6 (2 x CH2), 48.6 (2 x 
CH2). [ESI-HRMS] calculated for C14H19N4: 242.1531 [M+H]+. Found: 242.1536 
[M+H]+. 
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4.2.3. General method for the preparation of ethyl 1,4-bis(aryl)piperazine-2-
carboxylates (5). To a stirred solution of diamine (4) (1 m.eq., 2.84 g, 10.27 mmol) in 
anhydrous toluene at 80 °C (10 mL/mmol), was added triethylamine (2.5 m.eq.) and 
2,3-dibromopropionic acid ethyl ester (1.05 m.eq.) dropwise, and the reaction mixture 
was heated at 80 °C overnight. The solvent was evaporated and the residue extracted 
with CH2Cl2 (10 mL/mmol), washed with saturated aqueous NaHCO3 (5 x 5 mL/mmol) 
and brine (3 x 5 mL/mmol). The organic layer was dried (MgSO4), concentrated under 
reduced pressure, and crude product was purified by gradient flash column 
chromatography. 
4.2.3.1. Ethyl 1,4-bis(4-fluorobenzyl)piperazine-2-carboxylate (5a). Prepared from 
N1,N2-bis(4-fluorobenzyl)ethane-1,2-diamine (4a) (2.84 g, 10.27 mmol). The product 
was eluted with petroleum ether – EtOAc 87.5:12.5 v/v to give the product as a white 
solid, yield 2.49 g (65%). M.p. 46-48 oC. TLC (4:1 petroleum ether/EtOAc), Rf = 0.82. 
1H NMR (CDCl3): δ 7.29 (m, 4H, Ar), 6.99 (m, 4H, Ar), 4.19 (q, J = 7.0 Hz, 2H, 
CH2CH3), 3.89 (d, J = 13.3 Hz, 1H, H-7a), 3.58 (d, J = 13.0 Hz, 1H, H-7b), 3.53 (d, J = 
13.2 Hz, 1H, H-8a), 3.40 (d, J = 13.2 Hz, 1H, H-8b), 3.30 (dd, J = 3.6, 5.5 Hz, 1H, H-
2), 3.07 (m, 1H, H-3a), 2.76 (m, 1H, H-3b), 2.59-2.39 (m, 4H, H-6a,b, H-5a,b), 1.26 (t, J 
= 7.1 Hz, 3H, CH2CH3). 13C NMR (CDCl3): δ 172.0 (C=O), 163.0 (C, Ar), 162.9 (C, 
Ar), 161.1 (C, Ar), 161.0 (C, Ar), 130.5 (2 x CH, Ar), 130.4 (2 x CH, Ar), 130.3 (2 x 
CH, Ar), 130.2 (2 x CH, Ar), 62.6 (CH, piperazine), 61.8 (CH2CH3), 60.4 (CH2), 58.8 
(CH2), 55.4 (CH2, piperazine), 53.0 (CH2, piperazine), 48.5 (CH2, piperazine), 14.3 
(CH2CH3). 19F NMR (470 MHz, DMSO-d6): δ -115.99 (2 x C6H5F). [ESI-HRMS] 
calculated for C21H25F2N2O2: 375.1885 [M+H]+. Found: 375.1867 [M+H]+. 
4.2.3.2. Ethyl 1,4-bis(4-chlorobenzyl)piperazine-2-carboxylate (5b). Prepared from 
N1,N2-bis(4-chlorobenzyl)ethane-1,2-diamine (4b) (4.00 g, 12.93 mmol). The product 
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was eluted with petroleum ether – EtOAc 87.5:12.5 v/v to give the product as a white 
solid, yield 4.48 g (85%). M.p. 58-60 oC. TLC (4:1 petroleum ether/EtOAc), Rf = 0.60. 
1H NMR (CDCl3): δ 7.26 (m, 8H, Ar), 4.19 (q, J = 7.1 Hz, 2H, CH2CH3), 3.90 (d, J = 
13.5 Hz, 1H, H-7a), 3.59 (d, J = 11.6 Hz, 1H, H-7b), 3.54 (d, J = 13.4 Hz, 1H, H-8a), 
3.41 (d, J = 13.4 Hz, 1H, H-8b), 3.32 (m, 1H, H-2), 3.08 (m, 1H, H-3a), 2.77 (m, 1H, 
H-3b), 2.59 (m, 1H, H-6a), 2.53 (m, 1H, H-6b), 2.40 (m, 2H, H-5a,b), 1.26 (t, J = 7.1 Hz, 
3H, CH2CH3). 13C NMR (CDCl3): δ 172.1 (C=O), 163.0 (2 x C, Ar), 161.1 (2 x C, Ar), 
130.3 (4 x CH, Ar), 128.4 (4 x CH, Ar), 62.7 (CH, piperazine), 61.8 (CH2CH3), 60.4 
(CH2), 58.8 (CH2), 55.4 (CH2, piperazine), 53.1 (CH2, piperazine), 48.4 (CH2, 
piperazine), 14.0 (CH2CH3). Anal. Calcd for C21H24Cl2N2O2 (407.3335): C, 61.92; H, 
5.94; N, 6.87. Found: C, 61.66; H, 5.91; N, 6.84. 
4.2.3.3. Ethyl 1,4-bis(4-bromobenzyl)piperazine-2-carboxylate (5c). Prepared from 
N1,N2-bis(4-bromobenzyl)ethane-1,2-diamine (4c) (9.35 g, 23.48 mmol). The product 
was eluted with petroleum ether – EtOAc 87.5:12.5 v/v to give the product as a white 
solid, yield 9.68 g (83%). M.p. 64-66 oC. TLC (4:1 petroleum ether/EtOAc), Rf = 0.55. 
1H NMR (CDCl3): δ 7.44 (m, 4H, Ar), 7.20 (m, 4H, Ar), 4.19 (q, J = 7.1 Hz, 2H, 
CH2CH3), 3.89 (d, J = 13.6 Hz, 1H, H-7a), 3.59 (d, J = 13.4 Hz, 1H, H-7b), 3.52 (d, J = 
13.4 Hz, 1H, H-8a), 3.39 (d, J = 13.4 Hz, 1H, H-8b), 3.32 (dd, J = 3.4, 5.7 Hz, 1H, H-
2), 3.08 (m, 1H, H-3a), 2.79 (m, 1H, H-3b), 2.55-2.38 (m, 4H, H-6a,b, H-5a,b), 1.26 (t, J 
= 7.1 Hz, 3H, CH2CH3). 13C NMR (CDCl3): δ 171.9 (C=O), 137.5 (2 x C, Ar), 137.1 
(2 x C, Ar), 131.4 (2 x CH, Ar), 131.3 (2 x CH, Ar), 130.7 (2 x CH, Ar), 130.6 (2 x CH, 
Ar), 62.5 (CH, piperazine), 61.8 (CH2CH3), 60.5 (CH2), 58.9 (CH2), 55.4 (CH2, 
piperazine), 53.1 (CH2, piperazine), 48.4 (CH2, piperazine), 14.3 (CH2CH3). Anal. 
Calcd for C21H24Br2N2O2 (496.2355): C, 50.83; H, 4.84; N, 5.64. Found: C, 50.51; H, 
4.80; N, 5.57.  
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4.2.3.4. Ethyl 1,4-bis(3,5-dichlorobenzyl)piperazine-2-carboxylate (5d). Prepared from 
N1,N2-bis(3,5-dichlorobenzyl)ethane-1,2-diamine (4d) (6.0 g, 16.87 mmol). The 
product was eluted with petroleum ether – EtOAc 9:1 v/v to give the product as a buff 
solid, yield 4.46 g (71%). M.p. 80-84 oC. TLC (4:1 petroleum ether/EtOAc), Rf = 0.85. 
1H NMR (DMSO-d6): δ 7.79 (m, 2H, para-Ar), 7.36 (m, 4H, Ar), 4.09 (q, J = 7.1 Hz, 
2H, CH2CH3), 3.87 (d, J = 13.7 Hz, 1H, H-7a), 3.72 (d, J = 14.0 Hz, 1H, H-7b), 3.61 (d, 
J = 14.0 Hz, 1H, H-8a), 3.47 (d, J = 14.0 Hz, 1H, H-8b), 3.38 (m, 1H, H-2), 3.36 (m, 
1H, H-3a), 3.03 (m, 1H, H-3b), 2.78 (m, 1H, H-6a), 2.62 (m, 1H, H-6b), 2.44-2.30 (m, 
2H, H-5a,b), 1.15 (t, J = 7.1 Hz, 3H, CH2CH3). 13C NMR (DMSO-d6): δ 171.7 (C=O), 
144.4 (2 x C, Ar), 143.4 (2 x C, Ar), 134.4 (C, Ar), 134.3 (C, Ar), 127.5 (2 x CH, Ar), 
127.3 (2 x CH, Ar), 127.1 (CH, Ar), 126.9 (CH, Ar), 62.5 (CH, piperazine), 60.4 
(CH2CH3), 60.4 (CH2), 57.8 (CH2), 55.2 (CH2, piperazine), 53.3 (CH2, piperazine), 48.5 
(CH2, piperazine), 14.5 (CH2CH3). Anal. Calcd for C21H22Cl4N2O2 (476.2236): C, 
52.96; H, 4.66; N, 5.88. Found: C, 52.69; H, 4.57; N, 5.81. 
4.2.3.5. Ethyl 1,4-bis(4-ethylbenzyl)piperazine-2-carboxylate (5f). Prepared from 
N1,N2-bis(4-ethylbenzyl)ethane-1,2-diamine (4f) (9.0 g, 30.35 mmol). The product was 
eluted with petroleum ether – EtOAc 9:1 v/v to give the product as a colourless oil, 
yield 8.8 g (74%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.97. 1H NMR (DMSO-d6): δ 7.15 
(m, 8H, Ar), 4.06 (q, J = 7.7 Hz, 2H, CH2CH3), 3.79 (d, J = 13.4 Hz, 1H, H-7a), 3.57 
(d, J = 13.3 Hz, 1H, H-7b), 3.48 (d, J = 13.2 Hz, 1H, H-8a), 3.29 (m, 2H, H-8b, H-2), 
2.98 (m, 1H, H-3a), 2.69 (m, 1H, H-3b), 2.56 (q, J = 7.5 Hz, 4H, 2 x CH2CH3), 2.40 (m, 
4H, H-6a,b, H-5a,b), 1.15 (m,  9H, 3 x CH2CH3). 13C NMR (DMSO-d6): δ 171.7 (C=O), 
142.8 (2 x C, Ar), 135.6 (2 x C, Ar), 129.0 (4 x CH, Ar), 128.0 (4 x CH, Ar), 64.7 (CH, 
piperazine), 63.0 (CH2CH3), 61.9 (CH2), 60.7 (CH2), 58.8 (CH2, piperazine), 55.4 (CH2, 
piperazine), 53.3 (CH2, piperazine), 28.3 (2 x CH2CH3), 16.1 (2 x CH2CH3), 14.5 
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(CH2CH3). [ESI-HRMS] calculated for C25H35N2O2: 395.2699 [M+H]+. Found: 
395.2692 [M+H]+. 
4.2.3.6. Ethyl 1,4-bis(4-isopropylbenzyl)piperazine-2-carboxylate (5g). Prepared from 
N1,N2-bis(4-isopropylbenzyl)ethane-1,2-diamine (4f) (9.0 g, 27.73 mmol). The product 
was eluted with petroleum ether – EtOAc 9:1 v/v to give the product as a colourless oil, 
yield 10.0 g (85%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.98. 1H NMR (DMSO-d6): δ 7.17 
(m, 8H, Ar), 4.08 (q, J = 7.8 Hz, 2H, CH2CH3), 3.79 (d, J = 13.3 Hz, 1H, H-7a), 3.57 
(d, J = 13.2 Hz, 1H, H-7b), 3.48 (d, J = 13.1 Hz, 1H, H-8a), 3.27 (m, 2H, H-8b, H-2), 
2.99 (m, 1H, H-3a), 2.84 (sept, 2H, J = 6.8 Hz, 2 x CH(CH3)2), 2.70 (m, 1H, H-3b), 
2.47-2.30 (m, 4H, H-6a,b, H-5a,b), 1.17 (d, J = 7.0 Hz, 12H, 4 x CH3), 1.11 (t, J = 7.2 
Hz, 3H, CH2CH3). 13C NMR (DMSO-d6): δ 171.7 (C=O), 147.4 (2 x C, Ar), 136.3 (C, 
Ar), 135.8 (C, Ar), 129.0 (2 x CH, Ar), 128.9 (2 x CH, Ar), 126.5 (2 x CH, Ar), 126.4 
(2 x CH, Ar), 65.4 (CH, piperazine), 61.9 (CH2CH3), 60.2 (CH2), 60.1 (CH2), 58.8 (CH2, 
piperazine), 55.4 (CH2, piperazine), 53.4 (CH2, piperazine), 33.6 (2 x CH(CH3)2), 24.4 
(4 x CH3), 14.5 (CH2CH3). [ESI-HRMS] calculated for C27H39N2O2: 423.3012 [M+H]+. 
Found: 423.3016 [M+H]+. 
4.2.3.7. Ethyl 1,4-bis(4-(tert-butyl)benzyl)piperazine-2-carboxylate (5h). Prepared 
from N1,N2-bis(4-tert-butylbenzyl)ethane-1,2-diamine (4h) (6.0 g, 17.01 mmol). The 
product was eluted with petroleum ether – EtOAc 92.5:7.5 v/v to give the product as a 
white solid, yield 5.0 g (65%). M.p. 82-84 oC. TLC (5:1 petroleum ether/EtOAc), Rf = 
0.83. 1H NMR (CDCl3): δ 7.31 (m, 4H, Ar), 7.18 (m, 4H, Ar), 4.06 (q, J = 7.1 Hz, 2H, 
CH2CH3), 3.80 (d, J = 13.1 Hz, 1H, H-7a), 3.54 (d, J = 13.2 Hz, 1H, H-7b), 3.39 (m, 2H, 
H-8a,b), 3.30 (dd, J = 3.6, 5.6 Hz, 1H, H-2), 2.99 (m, 1H, H-3a), 2.72 (m, 1H, H-3b), 
2.41 (m, 4H, H-6a,b, H-5a,b), 1.25 (s, 18H, 6 x CH3), 1.11 (t, J = 6.7 Hz, 3H, CH2CH3). 
13C NMR (CDCl3): δ 171.5 (C=O), 135.8 (2 x C, Ar), 132.2 (2 x C, Ar), 128.8 (4 x CH, 
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Ar), 125.4 (4 x CH, Ar), 64.1 (CH, piperazine), 63.0 (CH2CH3), 61.8 (CH2), 60.3 (CH2), 
58.6 (CH2, piperazine), 53.2 (CH2, piperazine), 47.9 (CH2, piperazine), 34.6 (2 x 
C(CH3)3), 31.6 (6 x CH3), 14.5 (CH2CH3). [ESI-HRMS] calculated for C29H43N2O2: 
451.3324 [M+H]+. Found: 451.3327 [M+H]+. 
4.2.3.8. Ethyl 1,4-bis(pyridin-4-ylmethyl)piperazine-2-carboxylate (5i). Prepared from 
N1,N2-bis(pyridin-4-yl)ethane-1,2-diamine (4i) (3.66 g, 15.10 mmol). The product was 
eluted with CH2Cl2-MeOH-Et3N 97.5:1.5:1 v/v/v to give the product as a brown oil, 
yield 3.36 g (65%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.32. 1H NMR (DMSO-d6): δ 8.50 
(m, 4H, Ar), 7.30 (m, 4H, Ar), 4.10 (q, J = 7.6 Hz, 2H, CH2CH3), 3.90 (d, J = 13.0 Hz, 
1H, H-7a), 3.74 (d, J = 13.7 Hz, 1H, H-7b), 3.61 (d, J = 13.4 Hz, 1H, H-8a), 3.46 (d, J = 
13.4 Hz, 1H, H-8b), 3.40 (dd, J = 3.6, 5.9 Hz, 1H, H-2), 3.04 (m, 1H, H-3a), 2.81 (m, 
1H, H-3b), 2.58 (m, 1H, H-6a), 2.45 (m, 1H, H-6b), 2.36 (m, 2H, H-5a,b), 1.15 (t, J = 7.0 
Hz, 3H, CH2CH3). 13C NMR (DMSO-d6): δ 171.6 (C=O), 150.0 (4 x CH, Ar), 148.7 
(C, Ar), 147.7 (C, Ar), 124.0 (2 x CH, Ar), 123.8 (2 x CH, Ar), 62.0 (CH, piperazine), 
60.7 (CH2CH3), 60.4 (CH2), 57.8 (CH2), 55.4 (CH2, piperazine), 53.4 (CH2, piperazine), 
52.5 (CH2, piperazine), 14.6 (CH2CH3). [ESI-HRMS] calculated for C19H25N4O2: 
341.1899 [M+H]+. Found: 341.1910 [M+H]+. 
4.2.3.9. Ethyl 1,4-bis(pyridin-3-ylmethyl)piperazine-2-carboxylate (5j). Prepared from 
N1,N2-bis(pyridin-3-yl)ethane-1,2-diamine (4j) (3.50 g, 14.44 mmol). The product was 
eluted with CH2Cl2-MeOH-Et3N 96.5:2.5:1 v/v/v to give the product as a brown oil, 
yield 2.30 g (47%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.31. 1H NMR (DMSO-d6): δ 8.47 
(s, 2H, pyridine), 8.46 (m, 2H, pyridine), 7.67 (t, J = 7.7 Hz, 2H, pyridine), 7.35 (d, J 
= 5.6 Hz, 2H, pyridine), 4.08 (q, J = 7.8 Hz, 2H, CH2CH3), 3.88 (d, J = 14.0 Hz, 1H, 
H-7a), 3.70 (d, J = 13.8 Hz, 1H, H-7b), 3.60 (d, J = 13.5 Hz, 1H, H-8a), 3.38 (m, 2H, H-
8b, H-2), 3.00 (m, 1H, H-3a), 2.75 (m, 1H, H-3b), 2.54 (m, 1H, H-6a), 2.42 (m, 1H, H-
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6b), 2.34 (m, 2H, H-5a,b), 1.13 (t, J = 7.7 Hz, 3H, CH2CH3). 13C NMR (DMSO-d6): δ 
171.6 (C=O), 150.4 (CH, pyridine), 150.2 (CH, pyridine), 148.8 (CH, pyridine), 148.7 
(CH, pyridine), 136.9 (CH, pyridine), 136.6 (CH, pyridine), 134.7 (C, pyridine), 133.9 
(C, pyridine), 123.9 (CH, pyridine), 123.8 (CH, pyridine), 62.3 (CH, piperazine), 60.4 
(CH2CH3), 59.1 (CH2), 56.3 (CH2), 56.0 (CH2, piperazine), 55.2 (CH2, piperazine), 53.2 
(CH2, piperazine), 14.5 (CH2CH3). [ESI-HRMS] calculated for C19H25N4O2: 341.1899 
[M+H]+. Found: 341.1903 [M+H]+. 
4.2.4. General method for the preparation of alcohols (6). To an ice-cooled solution 
of ethyl carboxylate (5) (1 m.eq.) in dry THF (3 mL/mmol) was added LiAlH4 (1M in 
THF, 1.5 m.eq.) dropwise over 25 min. The reaction was then stirred at room 
temperature overnight, then cooled in an ice-bath and carefully quenched with H2O 
until cessation of effervescence. The reaction mixture was extracted with EtOAc (2 x 
10 mL/mmol), then the combined organic layers washed with H2O (3 x 10 mL/mmol), 
dried (MgSO4) and concentrated under reduced pressure. The crude product was 
purified by gradient flash column chromatography. 
4.2.4.1. (1,4-Bis(4-fluorobenzyl)piperazin-2-yl)methanol (6a). Prepared from ethyl 1,4-
bis(4-fluorobenzyl)piperazine-2-carboxylate (5a) (1.2 g, 3.20 mmol). The product was 
eluted with CH2Cl2-MeOH 95:5 v/v to give the product as a yellow oil, yield 0.86 g 
(81%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.55. 1H NMR (CDCl3): δ 7.30 (m, 8H, Ar), 
3.61 (m, 2H, H-9a,b), 3.48 (m, 2H, H-7a,b), 2.96 (m, 2H, H-8a,b), 2.67 (m, 3H, H-2, H-
3a,b), 2.59 (m, 1H, H-6a), 2.53-2.45 (m, 2H, H-6b, H-5a), 2.37 (m, 1H, H-5b). 13C NMR 
(CDCl3): δ 163.1 (C, Ar), 161.1 (C, Ar), 138.4 (C, Ar), 137.5 (C, Ar), 128.9 (4 x CH, 
Ar), 128.4 (4 x CH, Ar), 62.3 (CH2), 58.7 (CH, piperazine), 58.0 (CH2), 57.2 (CH2), 
55.9 (CH2, piperazine), 52.4 (CH2, piperazine), 49.9 (CH2, piperazine). 19F NMR 
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(CDCl3): δ -116.00 (2 x C6H5F). [ESI-HRMS] calculated for C19H23F2N2O: 333.1807 
[M+H]+. Found: 333.1823 [M+H]+. 
4.2.4.2. (1,4-Bis(4-chlorobenzyl)piperazin-2-yl)methanol (6b). Prepared from ethyl 
1,4-bis(4-chlorobenzyl)piperazine-2-carboxylate (5b) (1.0 g, 2.45 mmol). The product 
was eluted with CH2Cl2-MeOH 97:3 v/v to give the product as a colourless oil, yield 
0.52 g (59%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.59. 1H NMR (DMSO-d6): δ 7.30 (m, 
8H, Ar), 4.50 (t, J = 5.1 Hz, 1H, OH), 3.69 (m, 2H, H-9a,b), 3.43 (m, 2H, H-7a,b), 3.38 
(d, J = 13.6 Hz, 1H, H-8a), 3.27 (d, J = 13.6 Hz, 1H, H-8b), 2.73 (m, 1H, H-2), 2.59 (m, 
1H, H-3a), 2.48 (m, 1H, H-3b), 2.41 (m, 1H, H-6a), 2.18-2.02 (m, 3H, H-6b, H-5a,b). 13C 
NMR (DMSO-d6): δ 138.9 (C, Ar), 137.8 (C, Ar), 131.9 (C, Ar), 131.6 (C, Ar), 130.9 
(2 x CH, Ar), 130.8 (2 x CH, Ar), 128.6 (2 x CH, Ar), 128.5 (2 x CH, Ar), 62.7 (CH2), 
61.8 (CH, piperazine), 61.6 (CH2), 58.2 (CH2), 57.3 (CH2, piperazine), 52.9 (CH2, 
piperazine), 51.1 (CH2, piperazine). [ESI-HRMS] calculated for C19H23Cl2N2O: 
365.1187 [M+H]+. Found: 365.1190 [M+H]+. 
4.2.4.3. (1,4-Bis(4-bromobenzyl)piperazin-2-yl)methanol (6c). Prepared from ethyl 
1,4-bis(4-bromobenzyl)piperazine-2-carboxylate (5c) (1.20 g, 2.41 mmol). The product 
was eluted with CH2Cl2-MeOH 97.5:2.5 v/v to give the product as a white solid, yield 
0.89 g (81%). M.p. 88-90 oC. TLC (95:5 CH2Cl2/MeOH), Rf = 0.63. 1H NMR (DMSO-
d6): δ 7.49 (m, 4H, Ar), 7.25 (m, 4H, Ar), 4.54 (t, J = 5.1 Hz, 1H, OH), 3.66 (m, 2H, H-
9a,b), 3.42 (m, 2H, H-7a,b), 3.38 (d, J = 13.8 Hz, 1H, H-8a), 3.26 (d, J = 13.9 Hz, 1H, H-
8b), 2.69 (m, 1H, H-2), 2.56 (m, 1H, H-3a), 2.47 (m, 1H, H-3b), 2.40 (m, 1H, H-6a), 
2.17-2.02 (m, 3H, H-6b, H-5a,b). 13C NMR (DMSO-d6): δ 138.2 (2 x C, Ar), 131.5 (4 x 
CH, Ar), 131.2 (4 x CH, Ar), 120.3 (2 x C, Ar), 62.7 (CH2), 61.8 (CH, piperazine), 61.6 
(CH2), 58.1 (CH2), 56.4 (CH2, piperazine), 53.0 (CH2, piperazine), 51.1 (CH2, 
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piperazine). [ESI-HRMS] calculated for C19H23Br2N2O: 453.0177 [M+H]+. Found: 
453.0163 [M+H]+. 
4.2.4.4. (1,4-Bis(3,5-dichlorobenzyl)piperazin-2-yl)methanol (6d). Prepared from ethyl 
1,4-bis(3,5-dichlorobenzyl)piperazine-2-carboxylate (5d) (1.5 g, 3.14 mmol). The 
product was eluted with petroleum ether – EtOAc 7:3 v/v v/v to give the product as a 
yellow oil, yield 0.75 g (56%). TLC (1:1 petroleum ether/EtOAc), Rf = 0.31. 1H NMR 
(DMSO-d6): δ 7.46 (t, J = 1.7 Hz, 1H, para-Ar), 7.43 (t, J = 1.7 Hz, 1H, para-Ar), 7.36 
(d, J = 1.7 Hz, 2H, Ar), 7.33 (d, J = 1.7 Hz, 2H, Ar), 4.60 (t, J = 5.1 Hz, 1H, OH), 3.63 
(m, 2H, H-9a,b), 3.45 (m, 2H, H-7a,b), 3.37 (m, 2H, H-8a,b), 2.68 (m, 1H, H-2), 2.58 (m, 
1H, H-3a), 2.48 (m, 1H, H-3b), 2.43 (m, 1H, H-6a), 2.21-2.07 (m, 3H, H-6b, H-5a,b). 13C 
NMR (DMSO-d6): δ 142.5 (2 x C, Ar), 141.3 (2 x C, Ar), 133.4 (2 x C, Ar), 130.5 (CH, 
Ar), 130.4 (CH, Ar), 128.6 (CH, Ar), 128.5 (CH, Ar), 127.9 (CH, Ar), 127.7 (CH, Ar), 
61.7 (CH2), 61.6 (CH, piperazine), 61.5 (CH2), 57.4 (CH2), 56.9 (CH2, piperazine), 52.8 
(CH2, piperazine), 51.1 (CH2, piperazine). [ESI-HRMS] calculated for C19H21Cl4N2O: 
433.0408 [M+H]+. Found: 433.0399 [M+H]+. 
4.2.4.5. (1,4-Bis(4-ethylbenzyl)piperazin-2-yl)methanol (6f). Prepared from ethyl 1,4-
bis(4-ethylbenzyl)piperazine-2-carboxylate (5f) (2.0 g, 5.06 mmol). The product was 
eluted with CH2Cl2-MeOH 97:3 v/v to give the product as a buff solid, yield 1.48 g 
(83%). M.p. 40-42 oC. TLC (95:5 CH2Cl2/MeOH), Rf = 0.65. 1H NMR (DMSO-d6): δ 
7.18 (m, 8H, Ar), 4.52 (br s, 1H, OH), 3.70 (m, 2H, H-9a,b), 3.38 (m, 2H, H-7a,b), 3.22 
(d, J = 13.7 Hz, 1H, H-8a), 2.73 (d, J = 13.4 Hz, 1H, H-8b), 2.57 (q, J = 7.4 Hz, 4H, 2 
x CH2CH3), 2.38 (m, 1H, H-2), 2.14-2.02 (m, 6H, H-3a,b, H-6a,b, H-5a,b), 1.16 (t, J = 7.4 
Hz, 6H, 2 x CH3). 13C NMR (DMSO-d6): δ 142.7 (C, Ar), 142.4 (C, Ar), 136.8 (C, Ar), 
135.9 (C, Ar), 129.2 (2 x CH, Ar), 129.1 (2 x CH, Ar), 128.0 (2 x CH, Ar), 127.9 (2 x 
CH, Ar), 62.5 (CH2), 61.7 (CH, piperazine), 60.2 (CH2), 57.7 (CH2), 56.4 (CH2, 
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piperazine), 53.0 (CH2, piperazine), 51.1 (CH2, piperazine), 28.3 (2 x CH2CH3), 16.1 
(2 x CH2CH3). [ESI-HRMS] calculated for C23H33N2O: 353.2587 [M+H]+. Found: 
353.2610 [M+H]+. 
4.2.4.6. (1,4-Bis(4-isopropylbenzyl)piperazin-2-yl)methanol (6g). Prepared from ethyl 
1,4-bis(4-isopropylbenzyl)piperazine-2-carboxylate (5g) (2.50 g, 5.91 mmol). The 
product was eluted with CH2Cl2-MeOH 97:3 v/v to give the product as a buff solid, 
yield 1.91 g (85%). M.p. 68-70 oC. TLC (95:5 CH2Cl2/MeOH), Rf = 0.68. 1H NMR 
(DMSO-d6): δ 7.17 (m, 8H, Ar), 4.53 (br s, 1H, OH), 3.71 (m, 2H, H-9a,b), 3.40 (d, J = 
13.1 Hz, 1H, H-7a), 3.37 (d, J = 13.1 Hz, 1H, H-7b), 3.21 (d, J = 13.8 Hz, 1H, H-8a), 
2.85 (sept, J = 3.2 Hz, 2H, 2 x CH(CH3)2), 2.74 (d, J = 13.2 Hz, 1H, H-8b), 2.58 (m, 
1H, H-2), 2.47-2.39 (m, 2H, H-3a,b), 2.15-2.01 (m, 4H, H-6a,b, H-5a,b), 1.19 (d, J = 1.9 
Hz, 6H, 2 x CH3), 1.17 (d, J = 1.8 Hz, 6H, 2 x CH3). 13C NMR (DMSO-d6): δ 137.0 (2 
x C, Ar), 136.0 (2 x C, Ar), 129.2 (2 x CH, Ar), 129.0 (2 x CH, Ar), 126.5 (2 x CH, Ar), 
126.4 (2 x CH, Ar), 62.5 (CH2), 61.8 (CH, piperazine), 60.2 (CH2), 57.9 (CH2), 56.5 
(CH2, piperazine), 53.1 (CH2, piperazine), 51.2 (CH2, piperazine), 33.6 (2 x CH(CH3)2), 
24.4 (4 x CH3). [ESI-HRMS] calculated for C25H37N2O: 381.2900 [M+H]+. Found: 
381.2890 [M+H]+. 
4.2.4.7. (1,4-Bis(4-(tert-butyl)benzyl)piperazin-2-yl)methanol (6h). Prepared from 
ethyl 1,4-bis(4-tertbutylylbenzyl)piperazine-2-carboxylate (5h) (5 g, 11.09 mmol). The 
product was eluted with CH2Cl2-MeOH 97:3 v/v to give the product as a white solid, 
yield 4.12 g (91%). M.p. 92-94 oC. TLC (95:5 CH2Cl2/MeOH), Rf = 0.71. 1H NMR 
(DMSO-d6): δ 7.30 (m, 4H, Ar), 7.21 (m, 4H, Ar), 4.55 (br s, 1H, OH), 3.70 (m, 2H, 
H-9a,b), 3.41 (d, J = 13.2 Hz, 1H, H-7a), 3.23 (d, J = 13.1 Hz, 1H, H-7b), 2.77 (d, J = 
12.6 Hz, 1H, H-8a), 2.58 (d, J = 12.7 Hz, 1H, H-8b), 2.44 (m, 3H, H-2, H-3a,b), 2.41 (m, 
2H, H-6a,b), 2.06 (m, 2H, H-5a,b), 1.27 (s, 9H, 3 x CH3), 1.26 (s, 9H, 3 x CH3). 13C NMR 
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(DMSO-d6): δ 149.5 (C, Ar), 149.2 (C, Ar), 136.6 (C, Ar), 135.6 (C, Ar), 128.9 (2 x 
CH, Ar), 128.8 (2 x CH, Ar), 125.2 (2 x CH, Ar), 125.1 (2 x CH, Ar), 62.5 (CH2), 61.8 
(CH, piperazine), 60.2 (CH2), 57.9 (CH2), 56.6 (CH2, piperazine), 53.1 (CH2, 
piperazine), 51.2 (CH2, piperazine), 34.5 (2 x C(CH3)3), 31.6 (6 x CH3). [ESI-HRMS] 
calculated for C27H41N2O: 409.3213 [M+H]+. Found: 409.3215 [M+H]+. 
4.2.4.8. (1,4-Bis(pyridine-4-yl)piperazin-2-yl)methanol (6i). Prepared from ethyl 1,4-
bis(pyridin-4-yl)piperazine-2-carboxylate (5i) (0.96 g, 2.82 mmol). The product was 
eluted with CH2Cl2-MeOH-Et3N 89:10:1 v/v/v to give the product as a brown oil, yield 
0.60 g (71%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.25. 1H NMR (DMSO-d6): δ 8.49 (m, 
4H, Ar), 7.32 (m, 4H, Ar), 4.58 (t, J = 5.2 Hz, 1H, OH), 3.65 (m, 2H, H-9a,b), 3.49 (m, 
2H, H-7a,b), 3.39 (m, 2H, H-8a,b), 2.70 (m, 1H, H-2), 2.61 (m, 1H, H-3a), 2.46 (m, 1H, 
H-3b), 2.26-2.16 (m, 3H, H-6a,b, H-5a), 2.10 (m, 1H, H-5b). 13C NMR (DMSO-d6): δ 
136.8 (2 x C, pyridine), 129.3 (4 x CH, pyridine), 126.7 (4 x CH, pyridine), 62.5 (CH2), 
61.6 (CH, piperazine), 60.1 (CH2), 57.5 (CH2), 56.4 (CH2, piperazine), 52.9(CH2, 
piperazine), 51.4 (CH2, piperazine). [ESI-HRMS] calculated for C17H23N4O: 299.1872 
[M+H]+. Found: 299.1882 [M+H]+. 
4.2.4.9. (1,4-Bis(pyridine-3-yl)piperazin-2-yl)methanol (6j). Prepared from ethyl 1,4-
bis(pyridin-3-yl)piperazine-2-carboxylate (5j) (1.10 g, 3.23 mmol). The product was 
eluted with CH2Cl2-MeOH-Et3N 89:10:1 v/v/v to give the product as a brown oil, yield 
0.68 g (71%). TLC (95:5 CH2Cl2/MeOH), Rf = 0.24. 1H NMR (DMSO-d6): δ 8.49 (s, 
1H, pyridine), 8.47 (s, 1H, pyridine), 8.45 (m, 2H, pyridine), 7.70 (t, J = 7.7 Hz, 2H, 
pyridine), 7.34 (d, J = 5.6 Hz, 2H, pyridine), 4.57 (t, J = 5.2 Hz, 1H, OH), 3.70 (m, 2H, 
H-9a,b), 3.48 (m, 2H, H-7a,b), 3.41 (m, 2H, H-8a,b), 2.70 (m, 1H, H-2), 2.57 (m, 1H, H-
3a), 2.41 (m, 1H, H-3b), 2.20-2.04 (m, 4H, H-6a,b, H-5a,b). 13C NMR (DMSO-d6): δ 
150.1 (CH, pyridine), 149.8 (CH, pyridine), 148.5 (CH, pyridine), 147.6 (CH, pyridine), 
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136.8 (2 x CH, pyridine), 134.3 (2 x C, pyridine), 121.9 (2 x CH, pyridine), 62.4 (CH2), 
61.2 (CH, piperazine), 59.7 (CH2), 56.3 (CH2), 53.6 (CH2, piperazine), 51.3 (CH2, 
piperazine), 49.8 (CH2, piperazine). [ESI-HRMS] calculated for C17H23N4O: 299.1872 
[M+H]+. Found: 299.1879 [M+H]+. 
4.2.5. General method for the preparation of chlorides (7). To an ice-cooled solution 
of alcohol (6) (1 m.eq.) in dry CH2Cl2 (5 mL/mmol) was added thionyl chloride (10 
m.eq.) dropwise over 25 min. The reaction was stirred at room temperature for 48 h 
then cooled in an ice-bath and carefully quenched with saturated aqueous NaHCO3 in 
portions until slightly basic (pH 8.0). The organic layer was separated, washed with 
brine (3 x 10 mL/mmol), H2O (2 x 10 mL/mmol), dried (MgSO4) and evaporated under 
reduced pressure to give the chloride. Chloride products (7a-7d) that were highly 
sensitive to light and moisture were wrapped with aluminium foil, stored in the freezer 
immediately once prepared, and used in the next step without further purification. 
Stable chloride products (7f-7j) were purified by gradient column chromatography. 
4.2.5.1. 2-(Chloromethyl)-1,4-bis(4-fluorobenzyl)piperazine (7a). Prepared from  (1,4-
bis(4-fluorobenzyl)piperazin-2-yl)methanol (6a) (1.00 g, 3.00 mmol). The product was 
obtained as a brown solid, yield 0.52 g (50%). M.p. 66-68 oC. TLC (95:5 
CH2Cl2/MeOH), Rf = 0.91. 1H NMR (DMSO-d6): δ 7.36-7.12 (m, 8H, Ar), 3.93 (m, 
2H, H-9a,b), 3.84 (d, J = 13.2 Hz, 1H, H-7a), 3.49 (d, J = 13.3 Hz, 1H, H-7b), 3.41 (m, 
2H, H-8a,b), 2.71 (m, 1H, H-2), 2.61 (m, 1H, H-3a), 2.48 (m, 1H, H-3b), 2.31 (m, 4H, 
H-6a,b, H-5a,b). 13C NMR (DMSO-d6): δ 162.7 (2 x C, Ar), 139.3 (2 x C, Ar), 129.1 (2 
x CH, Ar), 128.7 (2 x CH, Ar), 115.5 (2 x CH, Ar), 115.3 (2 x CH, Ar), 61.5 (CH2), 
59.7 (CH, piperazine), 57.5 (CH2), 54.9 (CH2, piperazine), 54.7 (CH2, piperazine), 49.1 
(CH2, piperazine), 43.4 (CH2). 19F NMR (DMSO-d6): δ -115.99 (2 x C6H5F). [ESI-
HRMS] calculated for C19H22ClF2N2: 351.1440 [M+H]+. Found: 351.1449 [M+H]+. 
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4.2.5.2. 2-(Chloromethyl)-1,4-bis(4-chlorobenzyl)piperazine (7b). Prepared from  (1,4-
bis(4-chlorobenzyl)piperazin-2-yl)methanol (6b) (0.3 g, 0.82 mmol). The product was 
obtained as a brown solid, yield 0.21 g (68%). M.p. 64-66 oC. TLC (95:5 
CH2Cl2/MeOH), Rf = 0.92. 1H NMR (DMSO-d6): δ 7.33 (m, 8H, Ar), 3.95 (m, 2H, H-
9a,b), 3.48-3.36 (m, 4H, H-7a,b, H-8a,b), 2.72 (m, 1H, H-2), 2.60 (m, 1H, H-3a), 2.49 (m, 
1H, H-3b), 2.38 (m, 2H, H-6a,b), 2.28 (m, 2H, H-5a,b). 13C NMR (DMSO-d6): δ 139.1 (2 
x C, Ar), 131.8 (2 x C, Ar), 130.8 (2 x CH, Ar), 129.1 (2 x CH, Ar), 128.6 (2 x CH, Ar), 
127.3 (2 x CH, Ar), 62.4 (CH2), 59.7 (CH, piperazine), 58.1 (CH2), 57.5 (CH2, 
piperazine), 52.8 (CH2, piperazine), 49.2 (CH2, piperazine), 43.3 (CH2). [ESI-HRMS] 
calculated for C19H22Cl3N2: 383.0849 [M+H]+. Found: 383.0856 [M+H]+. 
4.2.5.3. 2-(Chloromethyl)-1,4-bis(4-bromobenzyl)piperazine (7c). Prepared from  (1,4-
bis(4-bromobenzyl)piperazin-2-yl)methanol (6c) (0.80 g, 1.76 mmol). The product was 
obtained as a light yellow solid, yield 0.53 g (64%). M.p. 70-72 oC. TLC (95:5 
CH2Cl2/MeOH), Rf = 0.94. 1H NMR (DMSO-d6): δ 7.50 (d, J = 8.3 Hz, 4H, Ar), 7.27 
(d, J = 8.3 Hz, 4H, Ar), 3.98 (m, 2H, H-9a,b), 3.85 (m, 2H, H-7a,b), 3.45 (m, 2H, H-8a,b), 
3.40 (m, 1H, H-2), 2.70 (m, 1H, H-3a), 2.60 (m, 1H, H-3b), 2.45 (m, 1H, H-6a), 2.37 (m, 
1H, H-6b), 2.26 (m, 2H, H-5a,b). 13C NMR (DMSO-d6): δ 137.7 (2 x C, Ar), 137.2 (2 x 
C, Ar), 131.4 (2 x CH, Ar), 131.3 (2 x CH, Ar), 130.6 (2 x CH, Ar), 130.4 (2 x CH, Ar), 
62.1 (CH2), 60.3 (CH, piperazine), 57.5 (CH2), 55.1 (CH2, piperazine), 52.7 (CH2, 
piperazine), 51.0 (CH2, piperazine), 42.3 (CH2). [ESI-HRMS] calculated for 
C19H22Br2ClN2: 470.9838 [M+H]+. Found: 470.9844 [M+H]+. 
4.2.5.4. 2-(Chloromethyl)-1,4-bis(3,5-dichlorobenzyl)piperazine (7d). Prepared from  
(1,4-bis(3,5-dichlorobenzyl)piperazin-2-yl)methanol (6d) (0.50 g, 1.15 mmol). The 
product was obtained as a brown oil, yield 0.31 g (60%). TLC (95:5 CH2Cl2/MeOH), 
Rf = 0.99. 1H NMR (DMSO-d6): δ 7.33 (m, 6H, Ar), 3.94 (m, 2H, H-9a,b), 3.85 (m, 2H, 
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H-7a,b), 3.52 (m, 2H, H-8a,b), 3.45 (m, 1H, H-2), 2.73 (m, 1H, H-3a), 2.63 (m, 1H, H-
3b), 2.40 (m, 1H, H-6a), 2.29 (m, 3H, H-6b, H-5a,b). 13C NMR (DMSO-d6): δ 142.1 (2 x 
C, Ar), 141.3 (2 x C, Ar), 133.4 (2 x C, Ar), 130.5 (2 x CH, Ar), 128.7 (CH, Ar), 128.6 
(CH, Ar), 127.7 (CH, Ar), 127.3 (CH, Ar), 61.5 (CH2), 59.7 (CH, piperazine), 57.6 
(CH2), 56.7 (CH2, piperazine), 54.9 (CH2, piperazine), 52.8 (CH2, piperazine), 43.4 
(CH2). [ESI-HRMS] calculated for C19H20Cl5N2: 451.0069 [M+H]+. Found: 451.0072 
[M+H]+. 
4.2.5.5. 2-(Chloromethyl)-1,4-bis(4-ethylbenzyl)piperazine (7f). Prepared from  (1,4-
bis(4-ethylbenzyl)piperazin-2-yl)methanol (6f) (1.35 g, 3.82 mmol). The product was 
purified by gradient column chromatography, eluting with petroleum ether –EtOAc 4:1 
v/v to give the product as a brown solid, yield 1.05 g (74%). M.p. 80-82 oC. TLC (3:1 
petroleum ether/EtOAc), Rf = 0.61. 1H NMR (DMSO-d6): δ 7.18 (m, 8H, Ar), 3.95 (m, 
2H, H-9a,b), 3.85 (m, 2H, H-7a,b), 3.42 (m, 2H, H-8a,b), 2.67 (m, 1H, H-2), 2.61 (m, 1H, 
H-3a), 2.57 (q, J = 7.1 Hz, 4H, 2 x CH2CH3), 2.44 (m, 1H, H-3b), 2.36 (m, 1H, H-6a), 
2.25 (m, 3H, H-6b, H-5a,b), 1.16 (t, J = 7.7 Hz, 6H, 2 x CH3). 13C NMR (125 MHz, 
DMSO-d6): δ 142.7 (2 x C, Ar), 136.2 (2 x C, Ar), 129.1 (4 x CH, Ar), 128.0 (4 x CH, 
Ar), 62.2 (CH2), 59.7 (CH, piperazine), 57.2 (CH2), 57.1 (CH2, piperazine), 52.8 (CH2, 
piperazine), 49.3 (CH2, piperazine), 43.5 (CH2), 28.29 (2 x CH2CH3), 16.08 (2 x 
CH2CH3). [ESI-HRMS] calculated for C23H32ClN2: 371.2249 [M+H]+. Found: 
371.2261 [M+H]+. 
4.2.5.6. 2-(Chloromethyl)-1,4-bis(4-isopropylbenzyl)piperazine (7g). Prepared from  
(1,4-bis(4-isopropylbenzyl)piperazin-2-yl)methanol (6g) (1.50 g, 3.94 mmol). The 
product was purified by gradient column chromatography, eluting with petroleum ether 
–EtOAc 4:1 v/v to give the product as a brown solid, yield 1.37 g (88%). M.p. 64-66 
oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.64. 1H NMR (DMSO-d6): δ 7.19 (m, 8H, 
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Ar), 3.95 (m, 2H, H-9a,b), 3.85 (m, 2H, H-7a,b), 3.41 (m, 2H, H-8a,b), 2.85 (m, 2H, 2 x 
CH(CH3)2), 2.68 (m, 1H, H-2), 2.60 (m, 1H, H-3a), 2.44 (m, 1H, H-3b), 2.36 (m, 1H, 
H-6a), 2.24 (m, 3H, H-6b, H-5a,b), 1.19 (s, 6H, 2 x CH3), 1.18 (s, 6H, 2 x CH3). 13C NMR 
(DMSO-d6): δ 147.5 (2 x C, Ar), 136.3 (2 x C, Ar), 129.1 (4 x CH, Ar), 126.5 (4 x CH, 
Ar), 62.2 (CH2), 59.7 (CH, piperazine), 57.19 (CH2), 55.4 (CH2, piperazine), 52.8 (CH2, 
piperazine), 49.2 (CH2, piperazine), 43.4 (CH2), 33.6 (2 x CH(CH3)2), 24.4 (4 x CH3). 
[ESI-HRMS] calculated for C25H36ClN2: 399.2562 [M+H]+. Found: 399.2569 [M+H]+. 
4.2.5.7. 2-(Chloromethyl)-1,4-bis(4-(tert-butyl)benzyl)piperazine (7h). Prepared from  
(1,4-bis(4-tertbutylbenzyl)piperazin-2-yl)methanol (6h) (2.0 g, 4.89 mmol). The 
product was purified by gradient column chromatography, eluting with petroleum ether 
–EtOAc 4:1 v/v to give the product as a brown solid, yield 1.72 g (83%). M.p. 110-112 
oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.66. 1H NMR (DMSO-d6): δ 7.25 (m, 8H, 
Ar), 3.97 (m, 2H, H-9a,b), 3.43 (d, J = 13.2 Hz, 1H, H-7a), 3.31 (d, J = 13.1 Hz, 1H, H-
7b), 2.79 (d, J = 12.6 Hz, 1H, H-8a), 2.61 (d, J = 12.7 Hz, 1H, H-8b), 2.46 (m, 3H, H-2, 
H-3a,b), 2.22 (m, 4H, H-6a,b, H-5a,b), 1.28 (s, 9H, 3 x CH3), 1.27 (s, 9H, 3 x CH3). 13C 
NMR (DMSO-d6): δ 149.3 (2 x C, Ar), 136.0 (2 x C, Ar), 128.9 (4 x CH, Ar), 125.1 (4 
x CH, Ar), 61.9 (CH2), 61.7 (CH, piperazine), 57.8 (CH2), 56.6 (CH2, piperazine), 53.2 
(CH2, piperazine), 50.7 (CH2, piperazine), 43.5 (CH2), 34.5 (2 x C(CH3)3), 31.5 (6 x 
CH3). [ESI-HRMS] calculated for C27H40ClN2: 427.2875 [M+H]+. Found: 427.2889 
[M+H]+. 
4.2.5.8. 2-(Chloromethyl)-1,4-bis(pyridine-4-ylmethyl)piperazine (7i). Prepared from  
(1,4-bis(pyridine-4-yl)piperazin-2-yl)methanol (6i) (0.60 g, 2.01 mmol). The product 
was purified by gradient column chromatography eluting with petroleum ether –EtOAc 
4:1 v/v to give the product as a colourless oil, yield 0.42 g (66%). TLC (2:1 petroleum 
ether/EtOAc), Rf = 0.59. 1H NMR (DMSO-d6): δ 8.50 (m, 4H, pyridine), 7.34 (m, 4H, 
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pyridine), 3.98 (m, 2H, H-9a,b), 3.85 (d, J = 13.9 Hz, 1H, H-7a), 3.55 (d, J = 13.5 Hz, 
1H, H-7b), 3.50 (m, 2H, H-8a,b), 2.77 (m, 1H, H-2), 2.65 (m, 1H, H-3a), 2.56 (m, 1H, 
H-3b), 2.43 (m, 1H, H-6a), 2.30 (m, 3H, H-6b, H-5a,b). 13C NMR (DMSO-d6): δ 150.0 
(2 x CH, pyridine), 149.9 (2 x CH, pyridine), 148.6 (2 x C, pyridine), 124.2 (2 x CH, 
pyridine), 124.0 (2 x CH, pyridine), 60.9 (CH2), 59.7 (CH, piperazine), 56.3 (CH2), 
55.4 (CH2, piperazine), 52.8 (CH2, piperazine), 49.2 (CH2, piperazine), 43.3 (CH2). 
[ESI-HRMS] calculated for C17H22ClN4: 317.1533 [M+H]+. Found: 317.1546 [M+H]+. 
4.2.5.9. 2-(Chloromethyl)-1,4-bis(pyridine-3-ylmethyl)piperazine (7j). Prepared from  
(1,4-bis(pyridine-3-yl)piperazin-2-yl)methanol (6j) (0.80 g, 2.68 mmol). The product 
was purified by gradient column chromatography eluting with petroleum ether–EtOAc 
4:1 v/v to give the product as a colourless oil, yield 0.68 g (81%). TLC (2:1 petroleum 
ether/EtOAc), Rf = 0.58. 1H NMR (DMSO-d6): δ 8.48 (m, 4H, pyridine), 7.71 (t, J = 
5.4 Hz, 2H, pyridine), 7.35 (d, J = 5.5 Hz, 2H, pyridine), 3.98 (m, 2H, H-9a,b), 3.87 (d, 
J = 13.4 Hz, 1H, H-7a), 3.54 (d, J = 13.5 Hz, 1H, H-7b), 3.47 (m, 2H, H-8a,b), 2.72 (m, 
1H, H-2), 2.62 (m, 1H, H-3a), 2.40 (m, 1H, H-3b), 2.30 (m, 2H, H-6a,b), 2.13 (m, 2H, 
H-5a,b). 13C NMR (DMSO-d6): δ 150.4 (CH, pyridine), 150.3 (CH, pyridine), 148.8 (CH, 
pyridine), 148.7 (CH, pyridine), 136.9 (CH, pyridine), 136.8 (CH, pyridine), 134.6 (2 
x C, pyridine), 123.9 (2 x CH, pyridine), 62.2 (CH2), 60.3 (CH, piperazine), 55.5 (CH2), 
54.8 (CH2, piperazine), 51.3 (CH2, piperazine), 48.9 (CH2, piperazine), 43.2 (CH2). 
[ESI-HRMS] calculated for C17H22ClN4: 317.1533 [M+H]+. Found: 317.1540 [M+H]+. 
4.2.6. General method for the preparation of imidazole derivatives (8). To a stirred 
suspension of K2CO3 (4 m.eq.) in dry acetonitrile (10 mL/4 mmol of K2CO3) was added 
imidazole (4 m.eq.). The reaction mixture was refluxed at 45 °C for 1 h. After cooling 
to room temperature the chloride (7) (1 m.eq.) was added and the reaction mixture 
refluxed at 70 °C for 48 h. The solvent was evaporated under reduced pressure and the 
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resulting mixture diluted with EtOAc (50 mL/mmol of chloride (7) used) and washed 
with brine (3 x 20 mL/mmol) and H2O (3 x 20 mL/mmol). The organic layer was dried 
(MgSO4) and evaporated under reduced pressure to give the crude imidazole, which 
was purified by gradient column chromatography. 
4.2.6.1. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-fluorobenzyl)piperazine (8a). 
Prepared from 2-(chloromethyl)-1,4-bis(4-fluorobenzyl)piperazine (7a) (0.50 g, 1.42 
mmol). The product was purified by gradient column chromatography eluting with 
CH2Cl2-MeOH 98:2 v/v, followed by further purification by preparative TLC (CH2Cl2-
MeOH 95:5 to 9:1 v/v) to give the product as a yellow oil*, yield 0.29 g (53%). TLC 
(95:5 CH2Cl2/MeOH), Rf = 0.50. 1H NMR (DMSO-d6): δ 7.47 (s, 1H, imidazole), 7.36-
7.11 (m, 8H, Ar), 6.97 (s, 1H, imidazole), 6.82 (s, 1H, imidazole), 4.30 (dd, J = 4.1, 
13.6 Hz, 1H, H-9a), 4.22 (dd, J = 7.0, 13.6 Hz, 1H, H-9b), 3.93 (d, J = 13.6 Hz, 1H, H-
7a), 3.59 (d, J = 13.2 Hz, 1H, H-7b), 3.44 (d, J = 13.2 Hz, 1H, H-8a), 3.32 (d, J = 13.2 
Hz, 1H, H-8b), 2.82 (m, 1H, H-2), 2.74 (m, 1H, H-3a), 2.30 (m, 4H, H-3b, H-6a,b, H-5a), 
2.12 (m, 1H, H-5b). 13C NMR (DMSO-d6): δ 139.3 (2 x C, Ar), 134.7 (2 x C, Ar), 131.2 
(2 x CH, Ar), 131.1 (2 x CH, Ar), 130.7 (CH, imidazole), 128.9 (2 x CH, Ar), 128.7 (2 
x CH, Ar), 127.3 (CH, imidazole), 120.3 (CH, imidazole), 61.6 (CH2), 59.3 (CH, 
piperazine), 57.7 (CH2), 56.8 (CH2), 55.4 (CH2, piperazine), 52.3 (CH2, piperazine), 
44.3 (CH2, piperazine). 19F NMR (DMSO-d6): δ -115.87 (2 x C6H4F). [ESI-HRMS] 
calculated for C22H25F2N4: 383.2047 [M+H]+. Found: 383.2050 [M+H]+. 
* The product was found to be unstable (light/moisture) so was wrapped in aluminium 
foil and stored in the freezer. 
4.2.6.2. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-chlorobenzyl)piperazine (8b). 
Prepared from 2-(chloromethyl)-1,4-bis(4-chlorobenzyl)piperazine (7b) (0.15 g, 0.39 
mmol). The product was purified by gradient column chromatography eluting with 
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CH2Cl2-MeOH 97.5:2.5 v/v, followed by further purification by preparative TLC 
(CH2Cl2-MeOH 95:5 v/v) to give the product as a colourless oil, yield 0.09 g (56%). 
TLC (95:5 CH2Cl2/MeOH), Rf = 0.60. 1H NMR (CDCl3): δ 7.24 (s, 1H, imidazole), 
7.22-7.12 (m, 8H, Ar), 6.89 (s, 1H, imidazole), 6.59 (s, 1H, imidazole), 4.28 (dd, J = 
4.3, 13.6 Hz, 1H, H-9a), 4.22 (dd, J = 7.7, 13.6 Hz, 1H, H-9b), 3.78 (d, J = 13.0 Hz, 1H, 
H-7a), 3.54 (d, J = 13.0 Hz, 1H, H-7b), 3.36 (d, J = 13.1 Hz, 1H, H-8a), 3.27 (d, J = 12.9 
Hz, 1H, H-8b), 2.80 (m, 1H, H-2), 2.76 (m, 1H, H-3a), 2.42 (m, 1H, H-3b), 2.40-2.13 
(m, 4H, H-6a,b, H-5a,b). 13C NMR (CDCl3): δ 138.1 (C, Ar), 136.9 (C, Ar), 136.4 (C, 
Ar), 133.0 (C, Ar), 130.4 (CH, imidazole), 128.6 (4 x CH, Ar), 128.5 (4 x CH, Ar), 
127.3 (CH, imidazole), 120.5 (CH, imidazole), 62.1 (CH2), 58.7 (CH, piperazine), 58.3 
(CH2), 53.8 (CH2), 52.2 (CH2, piperazine), 48.3 (CH2, piperazine), 44.1 (CH2, 
piperazine). [ESI-HRMS] calculated for C22H25Cl2N4: 415.1456 [M+H]+. Found: 
415.1447 [M+H]+. 
4.2.6.3. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-bromobenzyl)piperazine (8c). 
Prepared from 2-(chloromethyl)-1,4-bis(4-bromobenzyl)piperazine (7c) (0.4 g, 0.84 
mmol). The product was purified by gradient column chromatography eluting with 
CH2Cl2-MeOH 95:5 v/v to give the product as a white solid, yield 0.26 g (62%). M.p. 
54-56 oC. TLC (95:5 CH2Cl2/MeOH), Rf = 0.68. 1H NMR (CDCl3): δ 7.51 (s, 1H, 
imidazole), 7.49 (m, 4H, Ar), 7.26 (d, J = 8.2 Hz, 2H, Ar), 7.21 (d, J = 8.2 Hz, 2H, Ar), 
7.00 (s, 1H, imidazole), 6.83 (s, 1H, imidazole), 4.31 (dd, J = 4.6, 13.5 Hz, 1H, H-9a), 
4.20 (dd, J = 7.0, 13.5 Hz, 1H, H-9b), 3.89 (d, J = 14.0 Hz, 1H, H-7a), 3.57 (d, J = 14.2 
Hz, 1H, H-7b), 3.43 (d, J = 13.4 Hz, 1H, H-8a), 3.32 (d, J = 13.7 Hz, 1H, H-8b), 2.82 
(m, 1H, H-2), 2.75 (m, 1H, H-3a), 2.30 (m, 4H, H-3b, H-6a,b, H-5a), 2.10 (m, 1H, H-5b). 
13C NMR (CDCl3): δ 139.0 (2 x C, Ar), 138.0 (2 x C, Ar), 131.5 (CH, imidazole), 131.4 
(4 x CH, Ar), 131.0 (4 x CH, Ar), 128.6 (CH, imidazole), 120.4 (CH, imidazole), 61.7 
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(CH2), 59.3 (CH, piperazine), 56.8 (CH2), 54.1 (CH2), 52.2 (CH2, piperazine), 46.5 
(CH2, piperazine), 44.4 (CH2, piperazine). Anal. Calcd for C22H24Br2N4 (504.2608): C, 
52.40; H, 4.80; N, 11.11. Found: C, 52.30; H, 4.91; N, 11.20. 
4.2.6.4. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(3,5-dichlorobenzyl)piperazine (8d). 
Prepared from 2-(chloromethyl)-1,4-bis(3,5-dichlorobenzyl)piperazine (7d) (0.35 g, 
0.77 mmol). The product was purified by gradient column chromatography eluting with 
CH2Cl2-MeOH 99.8:0.2 v/v followed by further purification by preparative TLC 
(petroleum ether-EtOAc 3:2 v/v) to give the product as a colourless oil, yield 0.18 g 
(51%). TLC (1:1 petroleum ether/EtOAc), Rf = 0.94. 1H NMR (CDCl3): δ 7.47 (s, 1H, 
imidazole), 7.28 (s, 1H, para-Ar), 7.26 (s, 1H, para-Ar), 7.21 (s, 2H, Ar), 7.19 (s, 2H, 
Ar), 7.05 (s, 1H, imidazole), 6.77 (s, 1H, imidazole), 4.29 (dd, J = 4.1, 13.6 Hz, 1H, H-
9a), 4.21 (dd, J = 7.0, 13.6 Hz, 1H, H-9b), 3.79 (d, J = 14.0 Hz, 1H, H-7a), 3.64 (d, J = 
13.9 Hz, 1H, H-7b), 3.46 (d, J = 13.4 Hz, 1H, H-8a), 3.39 (d, J = 13.4 Hz, 1H, H-8b), 
2.96 (m, 1H, H-2), 2.88 (m, 1H, H-3a), 2.52 (m, 3H, H-3b, H-6a,b), 2.35 (m, 2H, H-5a,b). 
13C NMR (CDCl3): δ 142.1 (2 x C, Ar), 141.5 (2 x C, Ar), 135.1 (2 x C, Ar), 129.3 (CH, 
imidazole), 127.6 (2 x CH, Ar), 127.2 (2 x CH, Ar), 126.9 (CH, imidazole), 126.6 (2 x 
CH, Ar), 119.4 (CH, imidazole), 61.8 (CH2), 59.0 (CH, piperazine), 57.4 (CH2), 53.7 
(CH2), 52.0 (CH2, piperazine), 47.8 (CH2, piperazine), 44.2 (CH2, piperazine). [ESI-
HRMS] calculated for C22H23Cl4N4: 483.0677 [M+H]+. Found: 483.0678 [M+H]+. 
4.2.6.5. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-methoxybenzyl)piperazine (8e). 
Prepared from 2-(chloromethyl)-1,4-bis(4-methoxybenzyl)piperazine (7e) (0.35 g, 0.93 
mmol). The product was purified by gradient column chromatography eluting with 
CH2Cl2-MeOH 97.5:2.5 v/v followed by further purification by preparative TLC 
(CH2Cl2-MeOH 9:1 v/v) to give the product as a yellow oil, yield 0.25 g (68%). TLC 
(95:5 CH2Cl2/MeOH), Rf = 0.53. 1H NMR (DMSO-d6): δ 7.46 (s, 1H, imidazole), 7.19 
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(d, J = 8.5 Hz, 2H, Ar), 7.18 (d, J = 8.5 Hz, 2H, Ar), 6.96 (s, 1H, imidazole), 6.87 (d, J 
= 8.2 Hz, 4H, Ar), 6.81 (s, 1H, imidazole), 4.29 (dd, J = 4.4, 13.9 Hz, 1H, H-9a), 4.20 
(dd, J = 7.8, 13.9 Hz, 1H, H-9b), 3.84 (d, J = 13.0 Hz, 1H, H-7a), 3.73 (s, 6H, 2 x OCH3), 
3.51 (d, J = 12.9 Hz, 1H, H-7b), 3.39 (d, J = 12.8 Hz, 1H, H-8a), 3.25 (d, J = 12.8 Hz, 
1H, H-8b), 2.77 (m, 1H, H-2), 2.69 (m, 1H, H-3a), 2.30-2.22 (m, 4H, H-3b, H-6a,b, H-
5a), 2.09 (m, 1H, H-5b). 13C NMR (DMSO-d6): δ 142.8 (C, Ar), 142.7 (C, Ar), 134.6 
(C, Ar), 131.0 (C, Ar), 130.5 (2 x CH, Ar), 130.1 (2 x CH, Ar), 128.6 (CH, imidazole), 
128.1 (CH, imidazole), 120.1 (CH, imidazole), 114.1 (2 x CH, Ar), 114.0 (2 x CH, Ar), 
62.0 (CH2), 59.2 (CH, piperazine), 58.0 (CH2), 57.0 (CH2), 55.5 (2 x OCH3), 54.8 (CH2, 
piperazine), 54.3 (CH2, piperazine), 52.3 (CH2, piperazine). [ESI-HRMS] calculated 
for C24H31N4O2: 407.2442 [M+H]+. Found: 407.2438 [M+H]+. 
4.2.6.6. 2-((1H-imidazol-1-yl)methyl)-1,4-bis(4-ethylbenzyl)piperazine (8f). Prepared 
from 2-(chloromethyl)-1,4-bis(4-ethylbenzyl)piperazine (7f) (1.50 g, 4.04 mmol). The 
product was purified by gradient column chromatography eluting with CH2Cl2-MeOH 
99.5:0.5 v/v followed by further purification by preparative TLC (CH2Cl2-MeOH 95:5 
v/v) to give the product as a yellow oil, yield 1.12 g (69%). TLC (95:5 CH2Cl2/MeOH), 
Rf = 0.51. 1H NMR (DMSO-d6): δ 7.45 (s, 1H, imidazole), 7.16 (m, 8H, Ar), 6.93 (s, 
1H, imidazole), 6.80 (s, 1H, imidazole), 4.29 (dd, J = 4.3, 13.8 Hz, 1H, H-9a), 4.21 (dd, 
J = 7.7, 13.8 Hz, 1H, H-9b), 3.88 (d, J = 13.3 Hz, 1H, H-7a), 3.54 (d, J = 13.3 Hz, 1H, 
H-7b), 3.4 (d, J = 13.1 Hz, 1H, H-8a), 3.27 (d, J = 12.9 Hz, 1H, H-8b), 2.78 (m, 1H, H-
2), 2.71 (m, 1H, H-3a), 2.58 (m, 4H, 2 x CH2CH3), 2.31-2.24 (m, 3H, H-3b, H-6a,b), 2.11 
(m, 2H, H-5a,b), 1.17 (t, J = 7.58 Hz, 3H, CH2CH3), 1.16 (t, J = 7.6 Hz, 3H, CH2CH3). 
13C NMR (DMSO-d6): δ 142.9 (C, Ar), 142.7 (C, Ar), 136.5 (C, Ar), 135.7 (C, Ar), 
129.4 (2 x CH, Ar), 128.9 (2 x CH, Ar), 128.5 (CH, imidazole), 128.1 (2 x CH, Ar), 
128.0 (2 x CH, Ar), 126.4 (CH, imidazole), 120.3 (CH, imidazole), 62.3 (CH2), 59.3 
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(CH, piperazine), 58.8 (CH2), 57.4 (CH2), 55.4 (CH2, piperazine), 54.3 (CH2, 
piperazine), 52.4 (CH2, piperazine), 28.3 (CH2CH3), 28.2 (CH2CH3), 16.2 (CH2CH3), 
16.1 (CH2CH3). [ESI-HRMS] calculated for C26H35N4: 403.2862 [M+H]+. Found: 
403.2857 [M+H]+. 
4.2.6.7. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-isopropylbenzyl)piperazine (8g). 
Prepared from 2-(chloromethyl)-1,4-bis(4-isopropylbenzyl)piperazine (7g) (1.50 g, 
3.75 mmol). The product was purified by gradient column chromatography eluting with 
CH2Cl2-MeOH 99.7:0.3 v/v followed by further purification by preparative TLC 
(petroleum ether-EtOAc 3:2 v/v) to give the product as a brown solid, yield 1.02 g 
(63%). M.p. 110-112 oC. TLC (2:1 petroleum ether/EtOAc), Rf = 0.53. 1H NMR 
(DMSO-d6): δ 7.43 (s, 1H, imidazole), 7.19 (m, 8H, Ar), 6.90 (s, 1H, imidazole), 6.79 
(s, 1H, imidazole), 4.28 (dd, J = 4.4, 14.0 Hz, 1H, H-9a), 4.21 (dd, J = 7.8, 14.0 Hz, 1H, 
H-9b), 3.87 (d, J = 13.3 Hz, 1H, H-7a), 3.55 (d, J = 13.3 Hz, 1H, H-7b), 3.43 (d, J = 13.0 
Hz, 1H, H-8a), 3.26 (d, J = 13.0 Hz, 1H, H-8b), 2.85 (m, 2H, 2 x CH(CH3)2), 2.78 (m, 
1H, H-2), 2.71 (m, 1H, H-3a), 2.32-2.24 (m, 3H, H-3b, H-6a,b), 2.10 (m, 2H, H-5a,b), 
1.98 (d, J = 6.9 Hz, 6H, 2 x CH3), 1.89 (d, J = 6.8 Hz, 6H, 2 x CH3). 13C NMR (DMSO-
d6): δ 147.5 (C, Ar), 147.4 (C, Ar), 136.6 (C, Ar), 135.9 (C, Ar), 129.4 (2 x CH, Ar), 
128.9 (2 x CH, Ar), 128.5 (CH, imidazole), 126.6 (2 x CH, Ar), 126.5 (2 x CH, Ar), 
126.4 (CH, imidazole), 120.3 (CH, imidazole), 62.3 (CH2), 59.4 (CH, piperazine), 57.4 
(CH2), 56.9 (CH2), 55.4 (CH2, piperazine), 54.3 (CH2, piperazine), 52.5 (CH2, 
piperazine), 33.6 (2 x CH(CH3)2), 24.4 (4 x CH3). [ESI-HRMS] calculated for 
C28H39N4: 431.3175 [M+H]+. Found: 431.3186 [M+H]+. 
4.2.6.8. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(4-(tert-butyl)benzyl)piperazine (8h). 
Prepared from 2-(chloromethyl)-1,4-bis(4-tertbutylbenzyl)piperazine (7h) (1.50 g, 
3.51 mmol). The product was purified by gradient column chromatography eluting with 
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CH2Cl2-MeOH 99.8:0.2 v/v followed by further purification by preparative TLC 
(petroleum ether-EtOAc 3:2 v/v) to give the product as a yellow oil, yield 0.85 g (53%). 
TLC (2:1 petroleum ether/EtOAc), Rf = 0.55. 1H NMR (DMSO-d6): δ 7.43 (s, 1H, 
imidazole), 7.33 (m, 4H, Ar), 7.20 (m, 4H, Ar), 6.89 (s, 1H, imidazole), 6.78 (s, 1H, 
imidazole), 4.28 (dd, J = 4.3, 13.8 Hz, 1H, H-9a), 4.21 (dd, J = 7.6, 13.8 Hz, 1H, H-9b), 
3.87 (d, J = 13.7 Hz, 1H, H-7a), 3.56 (d, J = 13.7 Hz, 1H, H-7b), 3.44 (d, J = 12.8 Hz, 
1H, H-8a), 3.27 (d, J = 12.8 Hz, 1H, H-8b), 2.80 (m, 1H, H-2), 2.72 (m, 1H, H-3a), 2.36 
(m, 1H, H-3b), 2.29 (m, 2H, H-6a,b), 2.11 (m, 2H, H-5a,b), 1.28 (s, 9H, 3 x CH3), 1.27 
(s, 9H, 3 x CH3). 13C NMR (DMSO-d6): δ 149.8 (C, Ar), 149.6 (C, Ar), 136.2 (C, Ar), 
135.5 (C, Ar), 129.1 (2 x CH, Ar), 128.6 (2 x CH, Ar), 128.5 (CH, imidazole), 125.4 (2 
x CH, Ar), 125.3 (2 x CH, Ar), 125.2 (CH, imidazole), 120.3 (CH, imidazole), 62.2 
(CH2), 59.4 (CH, piperazine), 57.4 (CH2), 56.3 (CH2), 55.4 (CH2, piperazine), 54.3 
(CH2, piperazine), 52.5 (CH2, piperazine), 34.6 (2 x C(CH3)3), 31.7 (6 x CH3). [ESI-
HRMS] calculated for C30H43N4: 459.3488 [M+H]+. Found: 459.3490 [M+H]+. 
4.2.6.9. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(pyridine-4-ylmethyl)piperazine (8i). 
Prepared from 2-(chloromethyl)-1,4-bis(pyridine-4-ylmethyl)piperazine (7i) (0.4 g, 
1.26 mmol). The product was purified by gradient column chromatography, eluting 
with CH2Cl2-MeOH-Et3N 94:5:1 v/v/v, followed by further purification by preparative 
TLC (CH2Cl2-MeOH 9:1 to 85:15 v/v) to give the product as a yellow oil, yield 0.26 g 
(58%). TLC (1:9 CH2Cl2/MeOH), Rf = 0.57. 1H NMR (DMSO-d6): δ 8.47 (m, 4H, 
pyridine), 7.33 (s, 1H, imidazole), 7.15 (m, 4H, pyridine), 6.94 (s, 1H, imidazole), 6.68 
(s, 1H, imidazole), 4.28 (dd, J = 4.4, 14.0 Hz, 1H, H-9a), 4.21 (dd, J = 7.8, 14.0 Hz, 1H, 
H-9b), 3.79 (d, J = 14.0 Hz, 1H, H-7a), 3.58 (d, J = 14.0 Hz, 1H, H-7b), 3.49 (d, J = 13.4 
Hz, 1H, H-8a), 3.40 (d, J = 13.4 Hz, 1H, H-8b), 2.88 (m, 1H, H-2), 2.83 (m, 1H, H-3a), 
2.45-2.21 (m, 5H, H-3b, H-6a,b, H-5a,b). 13C NMR (CDCl3): δ 150.0 (2 x CH, pyridine), 
 45 
149.9 (2 x CH, pyridine), 137.5 (CH, imidazole), 137.3 (C, pyridine), 137.0 (C, 
pyridine), 129.5 (CH, imidazole), 123.8 (2 x CH, pyridine), 123.2 (2 x CH, pyridine), 
119.3 (CH, imidazole), 61.7 (CH2), 59.2 (CH, piperazine), 57.3 (CH2), 54.0 (CH2), 52.0 
(CH2, piperazine), 48.1 (CH2, piperazine), 44.5 (CH2, piperazine). [ESI-HRMS] 
calculated for C20H25N6: 349.2141 [M+H]+. Found: 349.2146 [M+H]+. 
4.2.6.10. 2-((1H-Imidazol-1-yl)methyl)-1,4-bis(pyridine-3-ylmethyl)piperazine (8j). 
Prepared from 2-(chloromethyl)-1,4-bis(pyridine-3-ylmethyl)piperazine (7j) (0.44 g, 
1.41 mmol). The product was purified by gradient column chromatography, eluting 
with CH2Cl2-MeOH-Et3N 94:5:1 v/v/v, followed by further purification by preparative 
TLC (CH2Cl2-MeOH 9:1 to 85:15 v/v) to give the product as a yellow oil, yield 0.25 g 
(53%). TLC (1:9 CH2Cl2/MeOH), Rf = 0.56. 1H NMR (DMSO-d6): δ 8.50 (s, 1H, 
pyridine), 8.49 (s, 1H, pyridine), 8.46 (m, 2H, pyridine), 7.71 (m, 2H, pyridine), 7.61 
(s, 1H, imidazole), 7.50 (s, 1H, imidazole), 7.34 (m, 2H, pyridine), 6.82 (s, 1H, 
imidazole), 4.29 (dd, J = 4.4, 13.8 Hz, 1H, H-9a), 4.21 (dd, J = 7.7, 13.8 Hz, 1H, H-9b), 
3.94 (d, J = 13.8 Hz, 1H, H-7a), 3.64 (d, J = 13.8 Hz, 1H, H-7b), 3.49 (d, J = 13.4 Hz, 
1H, H-8a), 3.39 (d, J = 13.4 Hz, 1H, H-8b), 2.86 (m, 1H, H-2), 2.75 (m, 2H, H-3a,b), 
2.32 (m, 3H, H-6a,b,H-5a), 2.13 (m, 1H, H-5b). 13C NMR (DMSO-d6): δ 150.2 (CH, 
pyridine), 149.6 (CH, pyridine), 148.6 (CH, pyridine), 148.5 (CH, pyridine), 137.3 (C, 
pyridine), 137.0 (C, pyridine), 136.4 (CH, imidazole), 135.3 (CH, pyridine), 129.0 (CH, 
pyridine), 124.0 (CH, imidazole), 121.8 (2 x CH, pyridine), 119.4 (CH, imidazole), 
60.1 (CH2), 58.8 (CH, piperazine), 55.5 (CH2), 53.3 (CH2), 51.9 (CH2, piperazine), 47.6 
(CH2, piperazine), 44.1 (CH2, piperazine). [ESI-HRMS] calculated for C20H25N6: 
349.2141 [M+H]+. Found: 349.2149 [M+H]+. 
4.3. CYP121A1 Spectral binding assays for ligand KD determination  
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CYP121A1 protein was expressed and purified as described previously.25 Ligand 
binding assays were performed by spectrophotometric titration using a Cary 60 UV-
visible scanning spectrophotometer (Agilent, UK) and a 1 cm path length quartz cuvette, 
recording spectra between 250 and 800 nm. Titrations were typically done with 3-5 μM 
CYP121A1 at 25 oC in 100 mM potassium phosphate (KPi) buffer, 200 mM KCl, pH 
7.85 with 0.004% Triton X-100. Ligand stock solutions were prepared in 
dimethylsulfoxide (DMSO). Ligands were added in small volumes (typically 0.05-0.2 
µL aliquots) from concentrated stock solutions to the protein in a 1 mL final volume. 
Spectral measurements were taken before ligand addition, and following addition of 
each aliquot of ligand until no further spectral change occurred. Difference spectra at 
each stage in the titration were obtained by subtraction of the initial ligand-free enzyme 
spectrum from subsequent spectra collected after each addition of ligand. From the 
difference spectra, a pair of wavelengths were identified and defined as the absorbance 
maximum (Apeak) and minimum (Atrough). The overall absorbance change (Amax) was 
calculated by subtracting the Atrough value from the Apeak value for each spectrum 
collected after a ligand addition. Graphs of Amax against [ligand] were plotted for 
each titration. Titrations were done in triplicate and the final KD value presented was 
determined as the average value across the three sets. The KD values were determined 
by fitting the data using either a standard hyberbolic function (Equation 1) or the Hill 
equation (Equation 2) using Origin software (OriginLab, Northampton, MA). 
Aobs = (Amax*L/(Kd+L))                            (Equation 1) 
In Equation 1 (the standard hyperbolic function, the Michaelis-Menten function 
adapted for ligand binding), Aobs is the observed absorbance change at ligand 
concentration L, Amax is the maximal absorbance change observed at apparent ligand 
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saturation, and Kd is the dissociation constant for the binding of the ligand (the substrate 
concentration at which Aobs = 0.5 x Amax). 
Aobs = (Amax × Ln)/(Kn+Ln)           (Equation 2) 
In Equation 2 (the sigmoidal Hill equation), Aobs is the observed absorbance change at 
ligand concentration L, Amax is the absorbance change at apparent ligand saturation, K 
is the apparent dissociation constant, and n is the Hill coefficient, a value describing 
the apparent extent of cooperativity observed in ligand binding. 
 
Antimycobacterial activity assay: M. tuberculosis H37Rv was grown in 7H9 liquid 
medium with 10 % Middlebrook OADC Growth Supplement enrichment 
(BBL/Becton-Dickinson, Sparks, MD, USA). Cells were cultured at 37 °C until mid-
log phase was reached (OD600nm = 0.4-0.6). After cells reached mid-log phase, bacterial 
suspensions were prepared as described below and REMA assays were performed. The 
anti-M. tuberculosis activities of the compounds were determined by the REMA 
(Resazurin Microtiter Assay) method.26  Stock solutions of the tested compounds (10 
mg/mL) were prepared in DMSO and diluted in Middlebrook 7H9 broth supplemented 
with 10% OADC. The microdilution of the compounds was performed in 96-well plates 
to obtain final compound concentration ranges of 0.39-100 µg/mL. Rifampicin in the 
concentration range between 0.004-1 µg/mL was added as control. Bacterial 
suspensions were prepared and their turbidity adjusted to match the optical density of 
McFarland no. 1 standard. After a further dilution of 1:20 in Middlebrook 7H9 broth 
supplemented with OADC, 100 µL of the inoculum were added to each well of the 96-
well plate. Cultures were incubated for 7 days at 37 °C, and 30 µL of 0.01% resazurin 
was added. Wells were read after 24 h for colour change and measured as the 
fluorescence (excitation/emission of 530/590 nm filters, respectively) in a 
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microfluorimeter. The MIC was defined as the lowest concentration resulting in 90 % 
inhibition of M. tuberculosis growth. The presented results are representative from two 
independent experiments. 
 
4.4. Computational methods 
4.4.1 Molecular Modeling and Docking  
Docking studies were performed using the MOE22 program and Mtb CYP121A1 co-
crystallised with cYY (PDB 3G5H). All minimisations were performed with MOE until 
a RMSD gradient of 0.01 Kcal/mol/A with the MMFF94 forcefield and partial charges 
were automatically calculated. The charge of the haem iron at physiological pH was set 
to 3+ (geometry d2sp3) through the atom manager in MOE. The Alpha Triangle 
placement, which derives poses by random superposition of ligand atom triplets 
through alpha sphere dummies in the receptor site, was chosen to determine the poses. 
estimates the free energy of binding of the ligand 
from a given pose. Refinement of the results was done using the MMFF94 forcefield, 
The output database dock file was created with different poses for each ligand and 
arranged according to the final score function (S), which is the score of the last stage 
that was not set to zero. 
4.4.2 Molecular Dynamics Simulation 
Molecular dynamics simulations were run on the CYP121A1 protein in complex with 8g and 
8h. Both PDB files were first optimised with protein preparation wizard in Maestro,27 version 
11.8.012 by assigning bond orders, adding hydrogen, and correcting incorrect bond types. A 
default quick relaxation protocol was used to minimise the MD systems with the Desmond 
programme.28 In Desmond, the volume of space in which the simulation takes place, the global 
cell, is built up by regular 3D simulation boxes, which was utilised as part in this system for 
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protein interactions. The orthorhombic water box allowed for a 10 Å buffer region between 
protein atoms and box sides. Overlapping water molecules were deleted, and the systems were 
neutralised with Na+ ions and salt concentration 0.15 M. Force-field parameters for the 
complexes were assigned using the OPLS_ 2005 forcefield, that is, a 50ns molecular dynamic 
run in the NPT ensemble (T = 300 K) at a constant pressure of 1 bar. Energy and trajectory 
atomic coordinate data were recorded at each 1.2 ns.  
 
 
Acknowledgements  
We thank the Egyptian Ministry of Higher Education-Missions Sector and the British 
Council for funding this research in Cardiff University through a Newton scholarship 
to SMAK and the EPSRC Mass Spectrometry Centre, Swansea, U.K. for mass 
spectroscopy data. AWM and KJM are grateful to the UK Biotechnology and 
Biological Sciences Research Council (BBSRC) for funding through grants 
BB/R009961/1, BB/I019227/1 and BB/R009961/1. SS and LPSC thank the Francis 
Crick Institute, which receives its core funding from Cancer Research UK (FC001060), 
the UK Medical Research Council (FC001060), and the Wellcome Trust (FC001060), 
and also the Wellcome Trust for a new investigator award to LPSC (104785/B/14/Z). 
Molecular dynamics simulations were undertaken using the supercomputing failities at 
Cardiff University operated by Advanced Research Computing at Cardiff (ARCCA) on 
behalf of the Cardiff Supercomputing Facility and the HPC Wales and Supercomputing 
Wales (SCW) projects. We acknowledge support of the latter, which is part-funded by 
the European Regional Development Fund (ERDF) via the Welsh Government. Our 
thanks to Thomas Green from ARCCA for his advice and support in using this facility. 
 
 50 
A. Supplementary data 
 Supplementary data associated with this article can be found, in the online 
version, at …………………….. 
 
 
References: 
(1)World Health Organization. Global tuberculosis report 2018. Available from: 
http://www.who.int/tb/publications/global_report/en/ (accessed January 3rd, 2019). 
(2) Mclean, K.J.; Munro, A.W. Structural biology and biochemistry of cytochrome 
P450 systems in Mycobacterium tuberculosis. Drug. Metab. Rev. 2008, 40, 427-446.  
(3) Nunn, A.J.; Jindani, A.; Enarson, D.A. Results at 30 months of a randomised trial 
of two 8-month regimens for the treatment of tuberculosis. Int. J. Tuberc. Lung Dis. 
2011, 15, 741-745.    
(4) Stagg, H.R.; Harris, R.J.; Hatherell, H.A.; Obach, D.; Zhao, H.; Tsuchiya, N.; 
Kranzer, K.; Nikolayevskyy, Y.; Kim, J.; Lipman, M.C.; Abubaker, I. What are the 
most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic 
review and network meta-analysis. Thorax. 2016, 71, 940-949.    
(5) Falzon, D.; Schünemann, H.J.; Harausz, E.; González-Angulo, L.; Lienhardt, C.; 
Jaramillo, E.; Weyer, K. World Health Organization treatment guidelines for drug 
resistant tuberculosis, 2016 Update. Eur. Respir. J. 2017, 49, 1602308.  
(6) Shleeva, M.O.; Kudykina, Y.K.; Vostroknutova, G.N.; Suzina, N.E.; Mulyukin, 
A.L.; Kaprelyants, A.S. Dormant ovoid cells of Mycobacterium tuberculosis are 
formed in response to gradual external acidification. Tuberculosis 2011, 91, 146-154.  
(7) Zhang, Y.; Yew, W.W.; Barer, M.R. Targeting persisters for tuberculosis control. 
Antimicrob. Agents Chemother. 2012, 56, 2223-2230.    
 51 
(8) Floyd, K.; Glaziou, P.; Zumla, A.; Raviglione, M. The global tuberculosis epidemic 
and progress in care, prevention, and research: an overview in year 3 of the End TB era. 
Lancet 2018, 6, 299-314.    
(9) Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, 
S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, 
D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; 
Hamlin, N.; Holroyd, S.; Hornby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; 
Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; 
Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.; Taylor, K.; 
Whitehead, S.; Barrell, B. Deciphering the biology of Mycobacterium tuberculosis 
from the complete genome sequence. Nature 1998, 393, 537-544.    
(10) Mclean, K.J.; Clift, D.; Lewis, D.G.; Sabri, M.; Balding, P.R.; Sutcliffe, M.J.; Leys, 
D.; Munro, A.W. The preponderance of P450s in the Mycobacterium tuberculosis 
genome. Trends Microbiol. 2006, 14, 220-228.    
(11) (64) Megehee, J.A.; Lundrigan, M.D. Temporal expression of Mycobacterium 
smegmatis respiratory terminal oxidases. Can. J. Microbiol. 2007, 53, 459-463.    
(12) Sassetti C.M.; Boyd, D.H.; Rubin, E.J. Genes required for mycobacterial growth 
defined by high density mutagenesis. Mol. Microbiol. 2003, 48, 77-84.    
(13) Sassetti C.M.; Boyd, D.H.; Rubin, E.J. Comprehensive identification of 
conditionally essential genes in mycobacteria. Proc. Natl. Acad. Sci. 2001, 98, 12712-
12717.    
(14) Mclean, K.J.; Carroll, P.; Lewis, D.G.; Dunford, A.; Seward, H.E.; Neeli, R.; 
Cheesman, M.R.; Marsollier, L.; Douglas, P.; Smith, W.E.; Rosenkrands, I.; Cole, S.T.; 
Leys, D.; Parish, T.; Munro, A.W. Characterization of active site structure in CYP121: 
a cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J Biol. 
 52 
Chem. 2008, 283, 33406-33416.  
(15) Gondry M, Sauguet L, Belin P, Thai, R.; Amouroux, R.; Tellier, C.; Tuphile, K.; 
Jacquet, M.; Braud, S.; Courçon, M.; Masson, C.; Dubois, S.; Lautru, S.; Lecoq, A.; 
Hashimoto, S.; Genet, R.; Pernodet, J.L. Cyclodipeptide synthases are a family of 
tRNA- dependent peptide bond–forming enzymes. Nat. Chem. Biol. 2009, 5, 414-420.  
(16) Vetting, M.W.; Hegde, S.S.; Blanchard, J.S. The structure and mechanism of the 
Mycobacterium tuberculosis cyclodityrosine synthetase. Nat. Chem. Biol. 2010, 6, 797-
799.    
(17) Belin, P.; Le Du, M.H.; Fielding A.; Lequin, O.; Jacquet, M.; Charbonnier, J.B.; 
Lecoq, A.; Thai, R; Courçon, M.; Masson, C.; Dugave, C.; Genet, R.; Pernodet, J.L.; 
Gondy, M. Identification and structural basis of the reaction catalyzed by CYP121, an 
essential cytochrome P450 in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 
2009, 106, 7426-7431.    
(18) Abd El-wahab, H.A.A.; Accietto, M.; Marino, L.B.; McLean, K.J.; Levy, C.W.; 
Abdel-Rahman, H.M.; El-Gendy, M.A.; Munro, A.W.; Aboraia, A.S.; Simons, C. 
Design, synthesis and evaluation against Mycobacterium tuberculosis of azole 
piperazine derivatives as dicyclotyrosine (cYY) mimics. Bioorg. Med. Chem. 2018, 26, 
161-176. 
(19) Taban, I.M.; Elshihawy, H.E.A.E.; Torun, B.; Zucchini, B.; Williamson, C.J.; 
Altuwairigi, D.; Ngu, A.S.T.; McLean, K.J.; Levy, C.W.; Sood, S.; Marino, L.B.; 
Munro, A.W.; de Carvalho, L.P.S.; Simons, C. Novel aryl substituted pyrazoles as 
small molecule inhibitors of cytochrome P450 CYP121A1: synthesis and 
antimycobacterial evaluation. J. Med. Chem. 2017, 60, 10257-10267.  
(20) Rondu, F.; Le Bihan, G.; Eang, X.; Lamouri, A.; Touboul, E.; Dive, G.; Bellahsene, 
T.; Pfeiffer, B.; Renard, P.; Guardiola-Lemaitre, B.; Manechez, D.; Penicaud, L.; 
 53 
Ktorza, A.; Godfroid, J.J.  Design and synthesis of imidazoline derivatives active on 
glucose homeostasis in a rat model of type ii diabetes. 1. Synthesis and biological 
activities of N-benzyl-N’-(arylalkyl)-2-(4 ′,5 ′-dihydro-1′ H-imidazol-2′-yl)piperazines. 
J. Med. Chem. 1997, 40, 3793–3803. 
(21) Labute, P. LowModeMD - Implicit low-mode velocity filtering applied to 
conformational search of macrocycles and protein loops. J. Chem. Inf. Model. 2010, 50, 
792–800. 
(22)  Molecular Operating Environment (MOE), 2015.10; Chemical Computing 
Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 
2016. 
(23) Stewart, J. J. P. Optimization of parameters for semiempirical methods. III 
Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and 
Bi. J. Comput. Chem. 1991, 12, 320–341. 
(24) Kallel, E. A.; Vangel, C.; Elbaum, D. Conformational analysis of 2-substituted 
piperazines. Bioorg. Med. Chem. Lett. 2016, 26, 3010–3013. 
(25) McLean, K.J.; Marshall, K.R.; Richmond, A.; Hunter, I.S.; Fowler, K.; Kieser, T.; 
Gurcha, S.S.; Besra, G.S.; Munro, A.W. Azole antifungals are potent inhibitors of 
cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and 
streptomycetes. Microbiology 2002, 148, 2937-2949. 
(26) Palomino, J.C.; Martin, A.; Camacho, M.; Guerra, H.; Swings, J.; Portaels, F. 
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug 
resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2002, 46, 
2720-2722. 
(27) Schrödinger Release 2019-1: Desmond Molecular Dynamics System, D. E. Shaw 
Research, New York, NY, 2019. Maestro-Desmond Interoperability Tools, 
 54 
Schrödinger, New York, NY, 2019. [https://www.schrodinger.com/Desmond/] 
(28) Bowers, K.J.; Chow, E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; 
Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; Salmon, J.K.; Shan, Y.; 
Shaw, D.E. Scalable algorithms for molecular dynamics simulations on commodity 
clusters. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), 
Tampa, Florida, 2006, November 11-17. 
(29) Husain, A.; Bhutani, R.; Kumar, D.; Shin, D. Synthesis and biological evaluation 
of novel substituted-imidazolidine derivatives. J. Korean Chem. Soc. 2013, 57, 227-
233. 
(30) Sharma, V.; Khan, M. S. Y. Synthesis of novel tetrahydroimidazole derivatives 
and studies for their biological properties. Eur. J. Med. Chem. 2001, 36, 651-658. 
(31) Arish, D.; Nair, M. S. Synthesis, spectroscopic, antimicrobial, DNA binding and 
cleavage studies of some metal complexes involving symmetrical bidentate N, N donor 
Schiff base ligand. Spectrochim. Acta A 2011, 82, 191–199. 
(32) Komatsu, H.; Ochiai, B.; Hino, T.; Endo, T. Thermally latent reaction of 
hemiacetal ester with epoxide controlled by Schiff-base-zinc chloride complexes with 
tunable catalytic activity. J. Mol. Catal. A-Chem. 2007, 273, 289–297. 
(33) Al-Lami, A. K. Preparation and mesomorphic characterization of supramolecular 
hydrogen-bonded dimer liquid crystals. Polycycl. Aromat. Comp. 2016, 36, 197–212. 
(34) Ouyang, X-M.; Fei, B-L.; Okamura, T-A.; Bu, H-W.; Sun, W-Y.; Tang, W-X.; 
Ueyama, N. Syntheses, crystal structures, and properties of four two-dimensional 
network complexes with multidentate bis(Schiff Base) ligands. Eur. J. Chem. 2003, (4), 
618-627. 
 55 
(35) Buchs, B.; Godin, G.; Trachsel, A.; de Saint Laumer, J-Y.; Lehn, J-M.; Herrmann, 
A. Reversible aminal formation: controlling the evaporation of bioactive volatiles by 
dynamic combinatorial/covalent chemistry. Eur. J. Org. Chem. 2011, (4) 681–695. 
 
 
 
       
 
 
 
